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Chapter 1 
 
General introduction  
 
 
 
 
 
 
 
 
 
 Chapter 1.1  2 
1.1 G-protein coupled receptors (GPCRs) 
 
1.1.1 GPCRs as drug targets 
 
Seven-transmembrane domain G-protein coupled receptors (GPCRs) constitute the largest 
and most diverse superfamily of cell surface receptors in the mammalian genome (Luttrell, 
2008) and represent around 15 % of the druggable genome (Hopkins and Groom, 2002). 
With alternative splicing, it is estimated that 1000-2000 discrete receptor proteins may be 
expressed (Luttrell, 2008). GPCRs detect a diversity of extracellular stimuli ranging from 
neurotransmitters and peptide hormones to odorants and photons of light and therefore 
influence a lot of important physiological functions (Luttrell, 2008). Consequently, GPCRs are 
involved in a plethora of diseases, e.g. cardiovascular, gastrointestinal and CNS disorders or 
asthma and cancer (Fang et al., 2003). As around 30 % of the currently marketed drugs 
address GPCRs, those receptors represent one of the most important classes for 
pharmacotherapy (Jacoby et al., 2006). Until now, at least 46 GPCRs have been 
successfully targeted by drugs, but there still remain 323 GPCRs that could become future 
drug targets. In addition, 150 of those 323 GPCRs are orphan receptors, i.e., their 
endogenous ligands are unknown so far (Lagerström and Schiöth, 2008).  
Thus, the (patho)physiological importance of those receptors opens a wide field for future 
developments with regard to basic research (de-orphanization) or to target already de-
orphanized receptors by innovative ligands.   
 
1.1.2 Structure and classification 
 
The current state of the research suggests a seven-transmembrane domain architecture for  
all GPCRs: the seven membrane spanning α-helices are linked by three alternating 
intracellular and extracellular loops. The transmembrane domains share the highest degree 
of sequence conservation, whereas the intracellular and extracellular domains exhibit 
extensive variability with regard to size and complexity. The extracellular and transmembrane 
regions are involved in ligand binding while the intracellular domains are important for signal 
transduction and for feedback modulation of receptor function (Luttrell, 2008). In Fig.1.1, a 
schematic representation of a GPCR (human histamine H2 receptor) in complex with one of 
its ligands (arpromidine) is shown. 
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Fig. 1.1: Model of the human histamine H2 
receptor in complex with the agonist arpromidine, 
based on the crystal structure of the β2-
adrenergic receptor (Cherezov et al., 2007). 
Transmembrane domains (TM) are illustrated in 
spectral colors: TM1: red, TM2: orange, TM3: 
yellow, TM4: green, TM5: greenblue, TM6: blue, 
TM7: purple. The homology model was created 
with SYBYL 7.3 (Tripos, St. Louis, USA) on a SGI 
Octane workstation. For further details see 
GHORAI (Ghorai et al., 2008).    
 
Important insights into the architecture of GPCRs were gained by determination of crystal 
structures. PALCZEWSKI and co-workers solved the crystal structure of bovine rhodopsin 
(Palczewski et al., 2000). More recently, the crystal structures of the human β2-adrenergic 
receptor (Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007) and the 
turkey β1-adrenergic receptor (Warne et al., 2008) were elucidated. Interestingly, the crystal 
structures of those receptors disclosed unexpected differences relative to bovine rhodopsin: 
the salt bridge between Arg3.50 and Glu6.30 ("ionic lock"), which stabilizes the inactive state in 
bovine rhodopsin, is lacking in both adrenergic receptor subtypes (Warne et al., 2008). Very 
recently, the crystal structure of the adenosine A2A receptor was solved (Jaakola et al., 
2008). In the latter, there is also a lack of the ionic lock (Hanson and Stevens, 2009). 
Furthermore, the extracellular region of rhodopsin occludes the ligand binding pocket, 
whereas in the β-adrenergic and the adenosine A2A receptors, the extracellular domains are 
highly constrained and held away from the ligand binding pocket opening. Those differences 
compromise the rhodopsin crystal structure as ideal representative for other GPCR family 
members (Hanson and Stevens, 2009). The recently elucidated crystal structures will 
contribute to an improved target-based drug design. Deeper insights into the structure of 
GPCRs can be gained from the reviews of HANSON (Hanson and Stevens, 2009) and 
TOPIOL (Topiol and Sabio, 2009).       
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GPCRs can be grouped by analysis of chromosomal positions and sequence fingerprints into 
five families according to the GRAFS classification system: Glutamate (G), Rhodopsin (R), 
Adhesion (A), Frizzled / Taste2 (F) and Secretin (S) (Fredriksson et al., 2003; Luttrell, 2008).  
The receptor families differ in several structural features, e.g. the length of the N-terminus, 
the presence or absence of a palmitoylation site in the C-terminal tail et cetera (Kristiansen, 
2004; Lagerström and Schiöth, 2008). For more detailed information on the classification of 
GPCRs, the reviews of KRISTIANSEN (Kristiansen, 2004) and LAGERSTRÖM (Lagerström 
and Schiöth, 2008) are recommended. 
The activation of GPCRs depends on their structural elements. At least the rhodopsin-like 
receptors are believed to be activated by a toggle switch of the transmembrane domain VI. 
Especially, the extracellular segment of this domain is supposed to tilt into the main ligand-
binding pocket, while the intracellular segment tilts away from the receptor and thereby 
opens the receptor for binding to the G-protein (see also section 1.1.3.1). The three main 
micro-switches, which contribute to receptor activation, are mediated by the amino acids 
Arg3.50, Trp6.50 and Tyr7.53 (Nygaard et al., 2009). Further interesting details with regard to 
GPCR activation were summarized in the review of NYGAARD (Nygaard et al., 2009).   
 
1.1.3 Signal transduction 
 
1.1.3.1 G-protein mediated signal transduction 
 
The binding of an agonist to the transmembrane or extracellular domains of a GPCR leads to 
conformational changes in the receptor protein that are transmitted to the intracellular 
domains. A G-protein, which consists of a Gα-subunit and a Gβγ-heterodimer, is activated on 
the inner membrane surface of the cell by interaction with the activated receptor: GDP, which 
is bound to the Gα-subunit in the inactive state, is released and immediately replaced by 
GTP. Thus, the activated GPCR acts as a guanine nucleotide exchange factor (GEF) for the 
G-protein. This exchange leads to the dissociation of the Gα-subunit from the Gβγ- 
heterodimer and the receptor. Consequently, various effector proteins are activated by those 
two G-protein components. Due to the intrinsic GTPase activity of the Gα-subunit, GTP is 
converted to GDP and Pi accompanied with the termination of the Gα-induced signal 
transduction and reassociation of the subunits (Cabrera-Vera et al., 2003; Luttrell, 2008). The 
hydrolysis of GTP is accelerated by regulators of G-protein signalling (RGS, (Cabrera-Vera 
et al., 2003)). The G-protein-cycle is schematically shown in Fig. 1.2. 
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Fig. 1.2: Activation of a heterotrimeric G-protein by interaction with an agonist-occupied GPCR. 
The activated receptor is represented by R*, whereas the inactive type is named R. Further 
details are described in the text (adapted from (Cabrera-Vera et al., 2003)).  
Both the Gα-subunit and the Gβγ-heterodimer are held in the cytoplasmic membrane and 
consequently in proximity to membrane proteins like GPCRs by lipid anchorage of the α- and 
the γ-subunit (Casey, 1994). A critical point for the interaction of the G-protein with the GPCR 
are the five C-terminal amino acids of the Gα-subunit as they interfere with the activated 
receptor (Bourne, 1997). Structural and functional similarities led to the classification of G-
proteins according to their Gα-subunits into four main families: GαS, Gα i, Gαq and Gα12 
(Cabrera-Vera et al., 2003). 
Members of the GαS family act by stimulation of adenylyl cyclase (AC). Consequently, the 
intracellular cAMP level is elevated, leading to the activation of proteinkinase A (PKA), a 
serine / threonine kinase phosphorylating numerous substrate proteins, resulting in a broad 
variety of cellular responses. For instance, the phosphorylation of the cAMP response 
element binding protein (CREB) influences transcription driven by the cAMP response 
element (CRE) (Hill et al., 2001). 
The activation of proteins which belong to the Gα i family results in a decrease in AC activity 
and therefore accounts for a reduction of the intracellular cAMP level. Thus, the inverse 
effects observed for the stimulation of GαS-subunits are induced (Hill et al., 2001).    
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Members of the Gαq family stimulate phospholipase Cβ (PLCβ) which cleaves phosphatidyl-
inositol-4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3). IP3 binds to IP3 receptors located in the membrane of the endoplasmic reticulum and 
evokes the release of calcium ions into the cytoplasm. Calcium and DAG can stimulate 
proteinkinase C (PKC) which in turn activates various intracellular proteins by 
phosphorylation (Thomsen et al., 2005). Members of the Gα12 family indirectly stimulate Rho 
A by interaction with RhoGEFs leading to further responses (Thomsen et al., 2005). 
In addition to the Gα-subunits, the Gβγ-heterodimers also evoke diverse cellular effects, e.g. 
activation of PLCβ, regulation of ion channels (Cabrera-Vera et al., 2003) or stimulation of 
the mitogen-activated-protein-kinase (MAPK) pathway by interaction with the small G-protein 
Ras (Hill et al., 2001).  
For more detailed information with regard to G-protein structure and signalling, the articles 
published by CABRERA-VERA (Cabrera-Vera et al., 2003) and SMRCKA (Smrcka, 2008) 
are recommended. 
 
1.1.3.2 Alternative pathways of signal transduction 
 
Besides the G-protein mediated signal transduction, alternative mechanisms of GPCR-
triggered cellular effects are discussed. One interesting point is the role of GPCRs as 
signalling scaffolds: for example, the β2-adrenergic receptor can be phosphorylated on 
tyrosine residues by the insulin receptor and subsequently directly associate with adapter 
proteins that control Ras activity (Karoor et al., 1997; Luttrell, 2008). In addition, the 
interaction of an agonist-occupied receptor with β-Arrestin in the scope of receptor 
desensitization could represent an alternative ternary complex (in contrast to the classical 
triad of agonist, receptor and G-protein) leading to an activation of the MAPK pathway 
(Luttrell, 2008; Miller and Lefkowitz, 2001; Perry and Lefkowitz, 2002). The alternative 
pathways of GPCR signaling are summarized in the review of LUTTRELL (Luttrell, 2008). 
  
1.1.4 Models of receptor activation and ligand classification 
 
The first attempts to describe the interaction of a ligand with its receptor were based on the 
law of mass action: CLARK assumed that the occupation of a receptor by a ligand evokes an 
effect (Clark, 1933; 1937). However, the discovery of G-proteins (Sternweis et al., 1981) 
revealed this theoretical approach as imperfect (Kenakin, 1989) and led to the development 
of the ternary complex model (TCM, (De Lean et al., 1980)). In the scope of the TCM, the 
occupation of the receptor by an agonist enables its interaction with the G-protein. The TCM 
contains four receptor species: the unoccupied receptor (R), the agonist-bound receptor 
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(AR), the receptor bound to the G-protein (RG) and the agonist-bound receptor with the G-
protein (ARG) forming the ternary complex (Fig. 1.3). 
  
AR+G ARG
A+RGA+R+G  
Fig. 1.3: Illustration of the ternary complex 
model (TCM). A: agonist, R: receptor, G: 
G-protein.  
 
As agonist-occupancy is regarded as a prerequisite for receptor activation, this model cannot 
explain constitutive activity of receptors, i.e., the active state of receptors in the absence of 
an agonist. In order to take this phenomenon into account, the extended ternary complex 
model (ETCM) was developed leading to six possible receptor species (Samama et al., 
1993). This model considers the two-state model (Leff, 1995): a receptor can adopt an active 
or inactive conformation independent of the presence or absence of an agonist.  
 
AR+G AR*+G
A+R*+GA+R+G
AR*G
A+R*G  
 
Fig. 1.4: Scheme of the extended ternary complex model (ETCM). R: inactive receptor 
conformation, R*: active receptor conformation, A: agonist, G: G-protein. 
The addition of a ligand shifts the equilibrium of the receptor states towards the preferred 
conformation. Agonists stabilize the active conformation of the receptor, whereas inverse 
agonists shift the equilibrium to the inactive state. Accordingly, partial agonists or partial 
inverse agonists shift the equilibrium to the particular conformation to a minor extent than full 
(inverse) agonists, respectively. Neutral antagonists do not differentiate between the two 
receptor states and do not change the basal activity of the receptor (Leff, 1995). Beyond this 
approach, the cubic ternary complex model (CTCM) considers the possible interaction of the 
inactive receptor with the G-protein. Thus, this model comprises eight receptor states (Fig. 
1.5, (Kenakin et al., 2000)). 
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AR+G AR*+G
A+R*+GA+R+G
AR*G
A+R*G
ARG
A+RG
 
 
Fig. 1.5: The cubic ternary complex model (CTCM). For explanation of R, R*, G and A see legend 
to Fig. 1.4.  
However, due to its complexity, the CTCM has just descriptive importance and is not 
appropriate for data analysis (Kenakin et al., 2000). 
The advent of allosteric ligands for GPCRs further complicated the establishment of an 
appropriate model of receptor activation. Allosteric ligands bind to sites that are different from 
the orthosteric site where the endogenous agonist binds (Bridges and Lindsley, 2008). Thus, 
a 16-point quaternary complex model is required for the description of interactions between 
the G-protein, the receptor, the orthosteric and the allosteric ligand (Christopoulos and 
Kenakin, 2002). Furthermore, the two-state model of the receptor activation is also a 
simplification disregarding the possible existence of multiple active state conformations (Kew 
et al., 1996; Perez and Karnik, 2005). 
Taken together, one must consider that all presented theoretical approaches remain models; 
none is capable to reflect the complete real situation. However, the ETCM can be regarded 
as an appropriate compromise of practicability and theory.            
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1.2 Histamine and its receptors 
 
1.2.1 The biogenic amine histamine 
 
Histamine is formed in the body by decarboxylation of the amino acid L-histidine by the 
enzyme L-histidine-decarboxylase (Schayer, 1956). Histamine can be inactivated by two 
pathways: in the scope of the major metabolic pathway, the N-nitrogen of the imidazole ring 
is methylated by histamine N-methyltransferase. The side chain is subsequently metabolized 
by diamine oxidase and xanthine oxidase. In addition, histamine can be inactivated without 
methylation: the amine is stepwise oxidized to the respective carboxylic acid by diamine or 
xanthine oxidase, respectively, and finally conjugated to ribose (Fig. 1.6, (Beaven, 1982)). 
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Fig. 1.6: Biosynthesis and metabolism of histamine.  
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Histamine exerts its biological effects through four receptor subtypes, designated H1, H2, H3 
and H4 receptors (H1R, H2R, H3R, H4R), respectively (de Esch et al., 2005). All those 
receptors belong to the class A (rhodopsin-like family) of GPCRs (Fredriksson et al., 2003).  
 
1.2.2 The histamine H1 receptor 
 
The hH1R was first cloned in 1993 (De Backer et al., 1993). The corresponding receptor 
protein consists of 487 amino acids and preferentially couples to Gq/11-proteins upon agonist-
stimulation (Hill, 1990). The signal is mainly transduced as explained in section 1.1.3.1 
resulting in an increase in the intracellular calcium level which can be monitored by 
fluorescent calcium-chelating dyes like fura-2 (see also chapter 3). In addition, the activation 
of the hH1R can also lead to an increase in the intracellular cAMP level (Esbenshade et al., 
2003). Human histamine H1 receptors are involved in a number of physiological events in the 
body. Most importantly, typical symptoms of allergic and inflammatory reactions are 
mediated by the activation of the H1R: in airway smooth muscle cells, a contraction is 
observed due to the stimulation with histamine (Kotlikoff et al., 1987). Mainly the stimulation 
of the H1R on endothelial cells leads to the release of EDRF (endothelium-derived relaxing 
factor) which provokes vasodilatation (Benedito et al., 1991). In addition, the activation of the 
H1R leads to a contraction of endothelial cells which accounts for an increase of the vascular 
permeability (Majno et al., 1969).  
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Fig. 1.7: Examples of H1R antagonists: A: mepyramine, B: dimethindene, C: 
diphenhydramine, D: triprolidine, E: cetirizine. Structures A-D represent first generation H1R 
antagonists, whereas compound E is a member of the second generation.  
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Accordingly, H1R antagonists were developed for the treatment of allergic diseases (Parsons 
and Ganellin, 2006). The first generation of H1R antagonists like mepyramine showed 
undesired effects on attention. Due to their high lipophilicity, those drugs can cross the blood 
brain barrier and consequently block human histamine H1 receptors in the CNS, which are 
involved in wakefulness and arousal. In order to damp this side effect, more hydrophilic 
compounds like cetirizine were developed (Hill et al., 1997). Examples for H1R antagonists 
are shown in Fig. 1.7. H1R-agonists are useful as pharmacological tools rather than as 
drugs. Betahistine is the only therapeutically used H1R agonist: it represents a weakly potent 
centrally acting drug and is used for the therapy of Menière’s Disease (Barak, 2008). 
Selective H1R agonists were obtained by introduction of moieties in position 2 of the 
imidazole moiety of histamine: whilst 2-methyl-histamine showed just poor potency on the 
H1R (Durant et al., 1975), 2-phenylhistamine and halogen-containing derivatives as 2-(3-
trifluormethylphenyl)histamine are featured with potencies comparable or even superior to 
histamine (Leschke et al., 1995; Zingel et al., 1990). Further approaches resulted in the more 
potent (supra)histaprodifens (Elz et al., 2000; Menghin et al., 2003). The elongation of the 
spacer in position 2 of the imidazole moiety from propyl to butyl led to histabudifen, a 
compound that addresses the H1R but is interestingly devoid of agonistic activity (Govoni et 
al., 2003). Especially the agonists of the suprahistaprodifen series represent valuable 
pharmacological tools.   
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Fig. 1.8: Chemical structure of the H1R antagonist histabudifen (C) and several H1R agonists: 
A: betahistine, B: 2-methylhistamine, D: 2-(3-trifluoromethylphenyl)histamine, E: histaprodifen, 
F: suprahistaprodifen. 
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1.2.3 The histamine H2 receptor 
 
The hH2R was first cloned in 1991 by GANTZ and coworkers (Gantz et al., 1991). The 
respective GPCR consists of 359 amino acids and couples to Gs-proteins leading to an 
increase of the intracellular cAMP level (Gantz et al., 1991). Furthermore, the stimulation of 
hH2R by agonists can lead to increases in the intracellular calcium level, possibly by coupling 
to Gq-proteins (Esbenshade et al., 2003). However, the mobilization of calcium due to  
receptor activation is not a common feature of the H2R: in CHO cells expressing the hH2R, 
no agonist-mediated increase of the intracellular calcium level was observed (Leurs et al., 
1994). The different observations of LEURS (Leurs et al., 1994) and ESBENSHADE 
(Esbenshade et al., 2003) with regard to calcium transients mediated by hH2R activation 
underline the dependence of signal transduction pathways on the used cellular system 
(Leurs et al., 1995) and, possibly, on other factors like transfection method, cell culture 
conditions et cetera. Therefore, with respect to assay development, in order to obtain robust 
calcium transients upon receptor activation, the stimulation of the hH2R should be redirected 
to the PLCβ signal transduction pathway (consider also chapters 2,4 and 5). Histamine H2 
receptors are located in the gastric mucosa and mediate the histamine induced increase in 
gastric acid secretion (Soll and Berglindh, 1987). Accordingly, H2R antagonists represent 
important drugs for the treatment of gastric ulcers (Black et al., 1972; Parsons and Ganellin, 
2006). Examples of H2R antagonists are shown in Fig. 1.9. 
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Fig. 1.9: Examples of H2R antagonists: A: cimetidine, B: famotidine, C: ranitidine, D: tiotidine.  
The H2R is also found in the heart: its stimulation by histamine leads to positive chronotropic 
and inotropic effects (Levi and Alloatti, 1988). Consequently, H2R agonists are of potential 
therapeutic interest for the treatment of congestive heart failure (Baumann et al., 1984). 
Especially agonists that incorporate a guanidine moiety like arpromidine and derivatives 
show a strongly increased potency as positive inotropic vasodilators compared to histamine 
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(Buschauer, 1989; Felix et al., 1995). However, those guanidine-type agonists have 
pharmacokinetic drawbacks like insufficient oral bioavailability. Recently, NG-acylated 
imidazolylpropylguanidines were described as H2R agonists with improved pharmacokinetic 
properties due to reduced basicity of the guanidine moiety. Prototypical acylguanidine-type 
H2R agonists were found to be orally available and brain-penetrating (Ghorai et al., 2008).  
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Fig. 1.10: Chemical structures of H2R agonists: A: amthamine, B: arpromidine, C: dimaprit,  
D: UR-AK24, a NG-acylated imidazolylpropylguanidine (further details are described in the text). 
The replacement of the imidazole moiety by a 2-amino-4-methylthiazol-5-yl ring known from 
the H2R agonist amthamine (Eriks et al., 1992) led to an improved selectivity for the H2R 
over other histamine receptor subtypes (Kraus et al., 2009). The linkage of two of those 
modified pharmacophoric entities resulting in bivalent ligands (twin compounds) increased 
the potency on the H2R (considerably for the chemical structure of such a compound see 
section 5.2.1.1; (Kraus, 2007)). As histamine H2 receptors are also present in the CNS, 
deeper insights into their function could be gained by investigations with H2R selective brain-
penetrating agonists. Histamine H2 receptors were proven to be involved in potentiation of 
excitation and in regulation of neuronal activity (Haas et al., 1988; Haas and Wolf, 1977).         
 
1.2.4 The histamine H3 receptor 
 
The hH3R was cloned in 1999 by LOVENBERG (Lovenberg et al., 1999). Interestingly, the 
cloned receptor shows only sequence homology to the hH1R and hH2R of about 20 %, which 
is comparable to other aminergic GPCRs (Lovenberg et al., 1999). In contrast to the hH1R 
and hH2R, the gene encoding the hH3R is organized in two introns and three exons 
(Wiedemann et al., 2002) or even three introns and four exons (Cogé et al., 2001b). With 
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alternative splicing, at least 20 isoforms of the receptor protein can emerge (Bongers et al., 
2007; Leurs et al., 2005). The best characterised hH3R isoform incorporates 445 amino acids 
(Lovenberg et al., 1999). Compared to the hH1R and hH2R, histamine shows remarkably 
increased affinity (EC50 in the nanomolar range) to this isoform of the hH3R (Lim et al., 
2005). The other hH3R isoforms consist of 200 to 453 amino acids (Bongers et al., 2007; 
Leurs et al., 2005). Receptor activation leads to the recruitment of Gi/o-proteins. The 
activated Gα i/o-subunit decreases AC activity. Therefore, the cAMP level is reduced and the 
subsequent effects described in section 1.1.3.1 are mediated. In addition, diverse effects on 
the intracellular calcium level are reported. Activation of the H3R can lead to a decrease of 
the Ca2+ influx through voltage-operated calcium channels (Bongers et al., 2007). In contrast, 
calcium mobilization from intracellular stores upon H3R stimulation is reported, too (Bongers 
et al., 2007). Furthermore, other signal transduction pathways are discussed for the H3R: 
inhibition of the Na+ / H+-exchanger is assumed as well as the stimulation of the phosphatidyl-
inositol-3-kinase- and MAPK-pathways or the activation of the phospholipase A2 (Bongers et 
al., 2007).  
The H3R acts as autoreceptor (Arrang et al., 1983) and is also thought to function as a 
heteroreceptor (Esbenshade et al., 2008). It is mainly located in the CNS (Lovenberg et al., 
1999) and shows hallmarks of constitutive activity (Morisset et al., 2000). In its function as an 
autoreceptor, the H3R regulates the synthesis (Arrang et al., 1987b) and release of histamine 
in the CNS (Arrang et al., 1983). Furthermore, the levels of neurotransmitters such as 
dopamine, serotonin, noradrenaline, acetylcholine and γ-amino butyric acid in the brain are 
modulated by activation of the H3R (Esbenshade et al., 2008; Sander et al., 2008). 
Accordingly, many targets for pharmacotherapy are discussed: H3R antagonists (inverse 
agonists) could become drugs against obesity (Tokita et al., 2006), schizophrenia (Browman 
et al., 2004; Prell et al., 1995), attention-deficit hyperactivity disorder (Horner et al., 2007), 
narcolepsy (Ligneau et al., 1998), Alzheimers disease (Giovannini et al., 1999) or nasal 
congestion (Varty et al., 2004). As H3R inverse agonists effectively increase the release of 
histamine, those compounds might be of special therapeutic interest (Morisset et al., 2000). 
However, inverse agonists may cause receptor up-regulation, which could be unfavourable in 
drug therapy (Leurs et al., 2005; Milligan and Bond, 1997). Comprehensive reviews with 
regard to H3R antagonists were recently published by ESBENSHADE (Esbenshade et al., 
2008) and SANDER (Sander et al., 2008). H3R agonists may play a role in the treatment of 
insomnia (Lin, 2000), pain (Cannon et al., 2003), inflammation (Cannon et al., 2007) or 
migraine (Millán-Guerrero et al., 2003). A classical H3R antagonist (inverse agonist) is 
thioperamide (Arrang et al., 1987a). However, after discovery of the hH4R this compound  
turned out to lack selectivity as it shows a similar affinity to both the hH3R and the hH4R (Lim 
et al., 2005). In order to increase the selectivity for the hH3R over the hH4R, "non-imidazoles" 
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such as JNJ-5207852 were developed (Barbier et al., 2004). The latter compound is a brain-
penetrating (Barbier et al., 2004) H3R antagonist supposed to have reduced affinity to 
cytochrome P450 enzymes (Sander et al., 2008). Classical H3R agonists are (R)-α-
methylhistamine (Arrang et al., 1987a) and Nα-methylhistamine (Babe and Serafín, 1996). 
Both agonists show selectivity for the hH3R relative to the hH4R (Lim et al., 2005) with higher 
hH3R selectivity residing in (R)-α-methylhistamine (Gbahou et al., 2006).  
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Fig. 1.11: Chemical structures of H3R antagonists (inverse agonists): A: thioperamide, B: 
JNJ-5207852, and H3R agonists: C: (R)-α-methylhistamine, D: Nα-methylhistamine.  
 
1.2.5 The histamine H4 receptor 
 
The hH4R was first cloned and functionally expressed in 2000 (Oda et al., 2000). The 
existence of the receptor was confirmed by several other workgroups (Liu et al., 2001; Morse 
et al., 2001; Nakamura et al., 2000; Nguyen et al., 2001; Zhu et al., 2001), however, those 
sequences slightly varied from the first reported one (de Esch et al., 2005). Showing a 
homology of 37 – 43 % (58 % in transmembrane regions), the hH4R is most closely related 
to the hH3R (Hough, 2001). The affinity of histamine to the hH3R and the hH4R is in the 
same range (Lim et al., 2005). The hH4R protein consists of 390 amino acids. Like the hH3R, 
the hH4R shows a relatively high constitutive activity (Morse et al., 2001). The hH4R gene is 
organized in two introns and three exons (Cogé et al., 2001a). This enables alternative 
splicing. Accordingly, the existence of two splice variants (hH4R(302) and hH4R(67), 
respectively) was recently reported (van Rijn et al., 2008). Those splice variants were mainly 
localized intracellularly, inactive with regard to ligand binding and had a dominant negative 
effect on the surface expression of the full-length hH4R(390) (van Rijn et al., 2008). Activation 
of the H4R leads to Gi/o-mediated signal transduction: Gα i/o-subunits inhibit AC activity which 
in turn decreases the cAMP level, the PKA activity and the CRE-driven transcription. The 
activation of Gβγ-subunits increases gene transcription by stimulation of the MAPK-pathway. 
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Furthermore, intracellular calcium transients emerge due to receptor activation, most 
probably mediated by the Gβγ-subunits (Lim et al., 2006). 
The H4R is discussed to play an important role in the immune system. It is localized on 
several immune cell types like basophils and mast cells (Hofstra et al., 2003), eosinophils 
(O'Reilly et al., 2002), dendritic cells (Damaj et al., 2007) and T-cells (Gantner et al., 2002). 
In eosinophils, H4R activation induces calcium mobilization, actin polymerization, 
upregulation of adhesion proteins, shape change and chemotaxis (Buckland et al., 2003; 
Ling et al., 2004). Chemotaxis and calcium mobilization are also reported for mast cells 
(Hofstra et al., 2003). However, calcium transients due to receptor activation are not a 
feature of recombinant expression systems (de Esch et al., 2005; Morse et al., 2001; Oda et 
al., 2000). Therefore, the coexpression of adapter proteins redirecting the stimulation of the 
H4R to robust calcium signals represents a reasonable approach to the development of a 
functional assay (see also chapter 2 and appendix). Due to the described effects mediated 
by H4R activation on immune cells, the blockade of this receptor by antagonists is 
considered a promising approach to the treatment of diseases like asthma, pruritus, 
rheumatoid arthritis or inflammatory bowel disease (Lim et al., 2006). In addition, a role of the 
H4R in colorectal and breast cancer is currently discussed (Cianchi et al., 2005; Maslinska et 
al., 2006). The first highly selective H4R antagonist was JNJ-7777120 (Jablonowski et al., 
2003). Current drug research in the hH4R field is focused on antagonists, mainly due to the 
prospect of new pharmacotherapies for the treatment of inflammatory diseases. The potential 
therapeutic value of H4R agonists is still unclear. However, selective agonists definitely 
represent valuable tools for the pharmacological investigation of the hH4R and its splice 
variants. An agonist with slight selectivity for the hH4R is OUP-16 (Hashimoto et al., 2003). 
Interestingly, 5-methylhistamine (also referred to as 4-methylhistamine), which was reported 
as a selective hH2R agonist in the 1970s, turned out to be considerably more potent as a 
hH4R agonist (Lim et al., 2005). In contrast to the aforementioned agonists, UR-PI376, a 
compound developed in our workgroup, is an hH4R selective agonist devoid of agonistic 
activity at other histamine receptor subtypes (Igel, 2008). 
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Fig. 1.12: Chemical structures of H4R ligands: A: the H4R antagonist JNJ-7777120; the H4R 
agonists OUP-16 (B), 5-methylhistamine (C) and UR-PI376 (D).    
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Within the research programme of the Graduiertenkolleg (Research Training Group) 
Medicinal Chemistry (GRK 760) at the University of Regensburg, special effort is made on 
the design, synthesis and pharmacological investigation of selective agonists and 
antagonists of histamine receptors. As a sub-project of this complex multidisciplinary project, 
this work is aiming at the development of binding and functional assays for the human 
histamine H1, H2 and H4 receptor, respectively. Such methods are required for the screening 
of compound libraries and the detailed pharmacological characterisation of substances with 
respect to affinity, potency and quality of action (agonism or antagonism), and receptor 
subtype selectivity.  
In order to economize the characterisation of ligand effects on hH1R-expressing cells, 
spectrofluorimetric measurements of agonist-mediated intracellular calcium mobilization 
using the fluorescent calcium chelator fura-2 ought to be adapted to the microtitre format. For 
assay validation, the agonist histamine and a series of reference antagonists will be 
investigated and compared with data reported in the literature. Since the applicability of the 
procedure for the investigation of compound libraries ought to be considered, different series 
of such libraries provided by Origenis GmbH (Martinsried, Germany) should be investigated 
for their effects on the hH1R with optimized assay parameters. Radioligand binding studies 
using the four human histamine receptor subtypes represents a straight forward approach in 
order to elaborate receptor-selectivity of hits identified in the screening programme. 
HEK293 cells will be investigated for their suitability to express human histamine receptor 
subtypes using mRNA analysis and Western Blot experiments. 
As histamine H2 receptors are coupling to Gs, cells will be genetically engineered by the 
cDNA encoding the hH2R and the chimeric G-protein qs5-HA in order to redirect the 
activation of the receptor to an increase in the intracellular calcium level. Calcium transients 
ought to be determined by fura-2 assay in a spectrofluorimetric or a microtitre format, 
respectively. Furthermore, cotransfection of the mitochondrially targeted apoaequorin should 
enable the performance of bioluminescence-based calcium measurements in the microtitre 
format.  
In order to explore the scope of applications of fluorescent selective histamine receptor 
ligands in cellular studies, fluorescence-labelled H2R ligands will be investigated for receptor 
binding on transfected cells using confocal microscopy and flow cytometry. For validation, 
the affinities of known H2R ligands will be determined in flow cytometric competition binding 
experiments using the fluorescent tracers. Additionally, for comparison of the 
pharmacological results from flow cytometric measurements with data determined by 
conventional methods, it is planned to establish a radioligand binding assay.   
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Although the assay procedures developed for the hH2R should in principle be transferable to 
the hH4R, cAMP measurements are planned in addition to the determination of calcium 
transients. 
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Adaptation of the fura-2 assay to the 
microtitre format for the screening 
 of ligands of the human histamine 
H1 receptor 
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3.1  Introduction 
 
Measurements of intracellular calcium transients are a popular method for the determination 
of ligand activity at GPCRs. Favoured readout systems are the FLIPR-assay which uses the 
non-ratiometric, calcium chelating dye fluo-4 or the aequorin-assay (Siehler, 2008; Takahashi 
et al., 1999). Both assays are applicable to the microtitre format (Siehler, 2008). In our 
workgroup, a spectrofluorimetric assay in cuvettes for the human histamine H1 receptor 
(hH1R) was developed using the ratiometric fluorescent dye fura-2 (Kracht, 2001). Fura-2 as 
a ratiometric Ca2+-indicator shows a shift of the excitation maximum upon Ca2+ binding (Fig. 
3.1). By measuring fluorescence emission intensities upon excitation at two different 
wavelengths, pairs of data are generated, of which a ratio can be calculated. Fura-2 is 
excited alternately at 340 and 380 nm and in both cases the fluorescence emission at 510 
nm is determined. Ratiometric dyes have several advantages over non-ratiometric indicators 
e.g. that the signal is nearly independent of intracellular dye concentration and almost not 
influenced by dye leakage. Moreover, the measurement is not affected by fluctuations in 
illumination intensity.  
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 Fig. 3.1: Spectral properties of the calcium-chelating dye fura-2. Increasing amounts of Ca2+ lead to an 
increased fluorescence intensity at 510 nm upon 
excitation with 340 nm, whereas the respective 
emission upon excitation with 380 nm is decreased 
(Gessele, 1998). 
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This study aimed at the exploitation of the ratiometic detection in microplates with respect to 
a higher throughput compared to measurements in cuvettes to save costs and time. When 
equipped with an injector, fluorescent plate readers such as the GENios Pro™ (Tecan, 
Salzburg, Austria) enable automatic measurements of calcium transients in either the 96-well 
or the 384-well format, respectively. 
As a GENios Pro™ plate reader was available, human U-373 MG glioblastoma cells, 
constitutively expressing the hH1R (Arias-Montaño et al., 1994) were investigated for calcium 
responses upon histamine challenge before the effects of hH1R-antagonists on the agonist 
mediated calcium signals were determined. Measurements were performed in the 96-well 
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and the 384-well format. The chemical structures of the investigated ligands can be found in 
the general introduction (chapter 1).  
As Origenis GmbH (Martinsried, Germany) is interested in substances for undisclosed 
pharmaceutical targets, different series of compound families provided by this company were 
investigated for their effects on the hH1R. In the scope of this cooperation, substances were 
both investigated in the 96-well and the 384-well format for their hH1R activity. The results 
from those investigations were considered for the optimization of specific biopharmacological 
parameters of different compound series in order to achieve the desired behaviour. 
Radioligand binding experiments were performed for all human histamine receptor subtypes 
in order to elaborate receptor-selectivity of selected potent compounds which were 
previously identified within the screening programme.  
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3.2 Materials and methods 
 
3.2.1 Cell culture 
 
The human U-373 MG (HTB-17) glioblastoma cells were obtained from the American Type 
Culture Collection (ATCC, Rockville, USA). Cells were cultured in Eagle´s minimum essential 
medium (EMEM, Sigma, Deisenhofen, Germany) containing L-glutamine, 2.2 g / L NaHCO3, 
110 mg / L sodium pyruvate and 5 % fetal bovine serum (FBS, Biochrom, Berlin, Germany). 
Cells were maintained in a water saturated atmosphere (95 % air / 5 % carbon dioxide) at 37 
°C in 75-cm² culture flasks (Nunc, Wiesbaden, Germany) and serially passaged following 
trypsinization using 0.05 % trypsin / 0.02 % EDTA. Passaging was performed once a week 
by 1:10 dilution after trypsin / EDTA treatment for approx. 5 min. The trypsin / EDTA stock 
solution (PAA, Pasching, Austria) was 1:10 diluted with phosphate buffered saline (PBS: KCl 
2.7 mM; KH2PO4 1.5 mM; NaCl 137 mM; Na2HPO4 5.6 mM; NaH2PO4 1.1 mM in Millipore 
water, pH 7.4; all chemicals were from Merck, Darmstadt, Germany) and sterile-filtered prior 
to use.  
Cell banking and quality control were performed according to the "seed stock concept" (Hay, 
1988). Every 3 months, cells were routinely monitored for Mycoplasma contamination by 
PCR, using the VenorGEM™ kit (Minerva Biolab, Berlin, Germany). Only Mycoplasma free 
cultures were used. 
For cryopreservation, cells were frozen by slow cooling (approx. 1 °C / min) in 9 parts of 
EMEM supplemented with 5 % FBS and 1 part of DMSO (p. a.) under sterile conditions: cells 
were stored in the refrigerator for at least 1 h, transferred into the -20 °C freezer for 4 h prior 
to the storage in the -80 °C freezer over night. Cells were stored under liquid nitrogen after 
the proof of the absence of mycoplasms. When required, cells were thawn from liquid 
nitrogen and reseeded at a relatively high concentration to optimize recovery. A cryo vial 
containing approx. 1 · 106 cells was immersed into a water bath at 37 °C and rapidly shaken. 
Cells were transferred to a 75-cm2 flask. 20 mL of EMEM containing 5 % FBS were added 
dropwise within 1 min. The cells were transferred to the CO2 incubator for 30 min. When the 
cells had adhered to the plastic surface, the DMSO-containing medium was removed and 
replaced by fresh cell culture medium.   
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3.2.2 Loading of U-373 MG cells with fura-2 / AM 
 
For fura-2 assays, the confluent cells of a 75-cm2 culture flask were trypsinized and 
passaged 1:5 into 175-cm2 culture flasks under sterile conditions. The cells were cultured in 
a CO2 incubator for 1 week at 37 °C.  
The cell culture medium was removed from the 175-cm2 culture flasks, cells were trypsinized 
and detached with EMEM containing 5 % of FBS for trypsine inactivation. Cells were 
centrifuged at 300 g (Minifuge 2, Heraeus Christ, Osterode, Germany, 5 min), washed and 
resuspended in loading buffer (NaCl 120 mM; KCl 5 mM; MgCl2 2 mM; CaCl2 1.5 mM; 
HEPES 25 mM; glucose 10 mM in Millipore water, pH 7.4; HEPES was from Serva, 
Heidelberg, Germany; all other chemicals were from Merck). Cells were counted and 
adjusted to a density of 1.3 · 106 cells / mL. 0.75 mL of cell suspension were added to 0.25 
mL of loading suspension containing 20 mg of BSA (Serva, Heidelberg, Germany), 5 µL of 
20 % Pluronic® F-127 / DMSO solution (Pluronic® F-127 was from Calbiochem-Novabiochem 
Corporation, La Joila, Canada, whereas DMSO was obtained from Merck) and 4 µL of fura-2 
/ AM (Invitrogen, Karlsruhe, Germany; 1 mM stock solution in anhydrous DMSO) in 1 mL of 
loading buffer. Final concentrations were: 1 · 106 cells / mL, 1 µM fura-2 / AM, 0.2 % DMSO 
and 0.025 % Pluronic® F-127. The cells were incubated at room temperature under light 
protection for 30 min, centrifuged and resuspended in the same volume of loading buffer. 
The cell suspension was incubated for another 30 min in order to ensure the complete 
intracellular cleavage of the AM-ester. Cells were washed and resuspended to a density of 1 
· 106 cells / mL prior to the assay. 
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Fig. 3.2: Cleavage of fura-2 / AM by intracellular esterases. The calcium chelating dye fura-2 is formed 
by hydrolysis of the ester. 
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3.2.3 Investigations on the suitability of the plate reader  
 
3.2.3.1  Ratiometric detection of Ca2+-complexation by fura-2 
 
10 µL of the fura-2 / AM stock solution (1 mM in anhydrous DMSO) were mixed with 4 µL of 
an esterase from porcine liver (Sigma, 4.6 U / µL of (NH4)2SO4 (3 M)) and 86 µL of sodium 
phosphate buffer (10 mM; pH = 7.4). Incubation was performed at 37 °C for 1 h. 
The reaction mixture was diluted with Millipore water to a final volume of 500 µL. 10 µL of this 
mixture were pipetted per cavity of a transparent 96-well plate (Greiner, Frickenhausen, 
Germany). 190 µL of calcium-buffers with concentrations ranging from 0 to 39 µM of free 
Ca2+ (Calcium Calibration Buffer Kit #2, Invitrogen) were added to the respective wells.  
The plate was inserted into the GENios Pro™ plate reader. 
Instrument settings were: measurement mode: endpoint; excitation wavelengths: 340 and 
380 nm (alternating), slits: 10 nm (in each case); emission wavelength: 535 nm, slit: 25 nm; 
gain: 40; number of reads: 3; integration time: 40 μs; lag time: 0 µs; mirror selection: top 
(dichroic mirror 3); time between move and flash: 100 ms.      
 
3.2.3.2  Effect of the injection-speed on the calcium signal 
 
20 µL of PBS were pipetted into the cavities of a transparent 96-well plate (Greiner).  
After 4 aquisition cycles (1 cycle equals to 0.66 s), 160 μL of the cell-suspension (1 · 106 cells 
/ mL) were added by injector A. After the 79th cycle, 20 μL of a 10-fold concentrated feed 
solution of histamine (300 μM in PBS; histamine was from Sigma) relative to the final 
concentration were inserted by injector B in order to elicit a calcium response in the fura-2 
loaded cells. The measurement was continued until cycle 200. 
Instrument settings were maintained according to section 3.2.3.1 with subsequent 
modifications: measurement mode: well kinetic; gain: 46-80 (as required for the respective 
experiment); mirror selection: bottom; well kinetic interval (minimal) 660 ms; injector A delay: 
2640 ms; injector B delay: 53040 ms; injector speed (injector A): 25-200 µL / s; injector 
speed (injector B): 200 µL / s; injection mode: standard.      
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3.2.4 Investigation of the effect of hH1R ligands on the mobilisation of 
intracellular calcium in U-373 MG cells 
 
3.2.4.1 Concentration-dependent increase in the intracellular calcium level by 
histamine 
 
The cavities of a transparent 96-well plate were loaded with 40 μL of 5-fold concentrated 
feed solutions of histamine relative to the final concentration (in PBS). Before the 5th cycle, 
160 μL of the gently stirred cell suspension (1 · 106 cells / mL) were added by injector A. 
Calcium signals were recorded until the 200th cycle was reached. The instrument settings 
were similar to those specified in 3.2.3.2, but the injection-speed of the cell suspension was 
reduced to 25 μL / s and the injector B was not used. Furthermore, measurements were 
performed from top with the dichroic mirror 3. 
Most of the instrument settings that were used for the investigation in the 96-well format were 
maintained in the 384-well format. Minor modifications were the reduction of the 
measurement time from 200 to 60 cycles and the raise of injection speed from 25 μL / s to 
200 μL / s. Furthermore, the volume of agonist and of injected cell suspension was reduced 
by a factor of 2 compared to the 96-well format.  
 
3.2.4.2  Investigation of H1R antagonists 
 
3.2.4.2.1 Optimisation of assay parameters 
 
In contrast to the agonist mode (section 3.2.4.1), in the antagonist mode injection of the fura-
2 / AM loaded cells did not provide reproducible results. Therefore, cells were preincubated 
with mepyramine in the microtitre plate before the injection of histamine. 
To construct a competiton curve with mepyramine (Sigma), several alternative approaches 
were performed by using the dichroic mirror 3 from top in the 96-well or the 384-well format, 
respectively.  
 
3.2.4.2.2 Investigation of standard antagonists in the optimized assay 
 
(R)-dimethindene, racemic dimethindene, triprolidine and levocetirizine were obtained from 
the Origenis company whereas mepyramine was from Sigma. 
10-fold concentrated feed solutions compared to the final assay concentration of the 
respective antagonist were prepared in PBS except levocetirizine: as this ligand is poorly 
soluble in PBS, the stock solution (10 mM) and the feed solution with the highest 
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concentration (100 µM) were prepared in 50 % DMSO / PBS (v/v). For the preparation of all 
lower concentrated feed solutions, PBS was used.  
10 μL of 10-fold concentrated feed solutions compared to the final concentration of the 
respective antagonist in PBS and 80 μL of the fura-2 / AM loaded cell-suspension were 
pipetted in the cavities of a transparent 384-well plate (Greiner). The plate was allowed to 
stand under light protection for 15 min at room temperature without movement or mixing. 
Calcium signals were evoked by injection of histamine (300 μM in PBS; 10 μL) before cycle 
5. Recordings were performed for 120 cycles.  
 
3.2.5    Screening of potential H1R ligands by the mobilisation of intracellular 
calcium in U-373 MG cells 
 
Transparent 96-well plates (Nunc) were prepared with 10-fold concentrated feed solutions 
compared to the final concentration of the respective ligands (20 µL in each case, in DMSO / 
PBS 2.5 % (v/v)) by the Origenis Company. U-373 MG cells were loaded with fura-2 
according to section 3.2.2. To enable shaking of the plate for 15 min (speed: 60 rpm, mode: 
orbital, settle time: 0 s) before starting the kinetic registration in the well kinetic mode, the 
absorbance of one representative well was measured in the endpoint mode (the software of 
the GENios Pro™ reader does not allow shaking without preceding injection). After this initial 
shaking step, the measurement mode was changed to well kinetics. The plate was shaked 
for another 30 s before the registration of each well kinetic for 160 cycles by injection of 
histamine (30 µM). 
36 compounds were characterised in duplicate per plate. 18 maximum signals and each 3 
wells containing mepyramine leading to final assay concentrations of 8 or 100 nM, 
respectively, were distributed on the plate.  
Transparent 384-well plates (Nunc) were assayed according to 3.2.4.2.2. In one assay, one 
half of the plate was investigated, the second part of the plate was stored at -20 °C and 
analyzed another day. 160 compounds were investigated in duplicate per plate. 32 maximal 
signals and each 16 wells with mepyramine according to final concentrations of 8 or 100 nM, 
respectively, were distributed on the plate.  
For the investigation of the concentration-dependent decrease in the intracellular calcium 
level, transparent 384-well plates were assayed as described in section 3.2.4.2.2 or with a 
reduced measurement time of 46 cycles, respectively. Ligands of interest were distributed on 
the plate as shown exemplarily in table 3.1. 32 maximal signals and 32 wells with 
mepyramine according to final assay concentrations of 0.1 to 100 nM were distributed on the 
plate. 
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 1 2 3 4 
A Max Max A1 A2 
B Max Max A3 A4 
C 0.5 5 B1 B2 
D 50 100 B3 B4 
E Max Max C1 C2 
F Max Max C3 C4 
G 0.1 10 D1 D2 
H 10 100 D3 D4 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Sector of a 384-well plate with compounds at various concentrations. Bold letters 
represent lines whereas bold numbers are columns of the plate. Italic numbers represent the final 
assay concentrations of mepyramine in [nM], Max are maximal signals and letters A-D represent 
investigated compounds according to various final assay concentrations in [µM] (1: 0.02; 2: 0.2; 3: 
2 and 4: 20 µM).  
 
 
 
3.2.6  Radioligand binding assays 
 
Compounds 1, 2, 3, 4 and 5 were further investigated by radioligand binding experiments. All 
binding studies were performed with membranes from Sf9 insect cells expressing the 
respective receptor subtype and appropriate radioactive tracers. As control, a high 
concentration of an antagonist for the receptor of interest was included in every assay (table 
3.2 and Fig. 3.3). 
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Table 3.2: Background information on the radioligand binding experiments. 
 
Receptor hH1R hH2R hH3R hH4R 
Additional 
proteins RGS4 GsαS Gα i2, Gβ1γ2, RGS4 Gα i2, Gβ1γ2 
Status of 
expression coexpression 
fusion protein 
(hH2R-GsαS) 
coexpression coexpression 
 Membrane 
protein per 
sample [µg] 
13 35 25 45 
Radioactive 
tracer 
[3H]-mepyramine 
(5 nM) 
[3H]-tiotidine 
(10 nM) 
[3H]-N-α-methylhistamine 
(1 nM) 
[3H]-histamine 
(10 nM) 
Antagonist 
(control) 
diphenhydramine 
(10 µM) 
famotidine 
(10 µM) 
thioperamide 
(10 µM) 
thioperamide  
(10 µM) 
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Fig. 3.3: Chemical structures of the radioactive tracers used for the assays: A: [3H]-mepyramine, B: 
[3H]-tiotidine, C: [3H]-N-α-methylhistamine,  D: [3H]-histamine. 
 
All radioactive tracers were from PerkinElmer Life Sciences (Boston, USA), famotidine was 
from Sigma, diphenhydramine and thioperamide were from Tocris Cookson (Ballwin, USA).  
The chemical structures of the antagonists used as positive controls can be found in the 
general introduction (chapter 1). 
Membranes were thawed, centrifuged (15 min at 4°C and 15,000 g) and resuspended in 
binding buffer (12.5 mM MgCl2, 1 mM EDTA, 75 mM Tris / HCl, pH 7.4; MgCl2 and EDTA 
were from Merck whereas Tris / HCl was from Serva). For the preparation of the samples, 
150 µL of binding buffer including 0.33 % BSA were mixed with 25 µL of the compounds (10-
fold concentrated feed solutions compared to the final concentration in 10 % DMSO) and 25 
µL of the radioactive tracer (10-fold concentrated feed solution compared to the final con-
centration). Samples were completed by addition of the membrane suspension (50 µL per 
sample).  
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Incubations were conducted for 60 min at room temperature under continuous shaking (250 
rpm). Free radioactive tracer was separated by filtration through GF / C filters (Whatman, 
Kent, UK) that were pretreated with 0.3 % polyethylenimine (v/v) (undiluted polyethylenimine 
was from Sigma) 10 min prior to the suction by the M-48 Robotic Cell Harvester (Brandel, 
Gaithersburg, USA). Samples were washed three times with 2 mL of binding buffer (4 °C). 
Filterdiscs were transferred into 6 mL mini-vials (Sarstedt, Nümbrecht, Germany). Every vial 
was filled with 3 mL of Rotiszint® eco plus (Carl Roth, Karlsruhe, Germany) and closed. 
Samples were collected in racks and inversed 15 times in order to elute radioactivity from the 
filter discs into the fluid. Samples were stored under light protection in the LS 6500 Liquid 
Scintillation Counter (Beckman Coulter, Krefeld, Germany) for at least 30 min in order to 
diminish errors due to light irradiation. Samples were counted in the automatic mode 
(measurement time: 5 min for each sample).  
 
3.2.7 Data analysis 
 
Ratios were determined from raw data in Microsoft® Office Excel 2003. Increases of the 
intracellular calcium level were determined by subtraction of the ratio recorded before the 
injection of loaded cells (agonists) or histamine (antagonists) from the maximal ratio which 
was detected after the injection process. For the determination of agonistic potencies, ligand-
induced increases in the intracellular calcium level were related to those calculated for 100 
µM of the reference compound histamine (maximal signal in the agonist mode) in %. The 
blank value (PBS without histamine) was subtracted from all values and the resulting 
differences were again related on 100 µM of histamine in %.  
In the case of the characterisation of antagonists, the calcium responses to histamine 
determined in the presence of the test compound were related to the maximal increases in 
%. Plots were created with the multiple scatter error bars option in SigmaPlot® 9.0. Curve 
fitting was performed according to the standard curves, four parameter logistic function. 
 
 Chapter 3.3  40 
3.3 Results and discussion 
 
3.3.1 Investigations on the suitability of the plate reader  
 
3.3.1.1  Ratiometric detection of Ca2+-complexation by fura-2 
 
Using the GENios Pro™ plate reader, a saturation of fura-2 by increasing concentrations of 
Ca2+ was detected indicating the adequacy of the optical setup of the instrument (Fig. 3.4). 
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Fig. 3.4: Saturation of fura-2 by increasing 
concentrations of Ca2+ (mean values ± 
SEM; n = 3). Calcium-signals were 
registered as the ratio of emission at 510 
nm after excitation at 340 nm and 380 nm, 
respectively.  
 
 
 
3.3.1.2  Effect of the injection of the cells on the calcium signal 
 
Interestingly, the injection of the loaded cells at a speed of 200 μL / s led to an increase of 
the ratio before the injection of the agonist (Fig. 3.5). The explanation for this observation is 
the damage of the cells due to shear stress by injection. This undesired effect is avoided by 
the reduction of the injection-speed to 25 μL / s (Fig. 3.5). Hence, this injection-speed was 
chosen for experiments in the 96-well format (3.3.2.1). 
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Fig. 3.5: Effect of the injection-speed on the calcium signal. Injection of the fura-2 / AM loaded cells at 
a speed of 200 µL / s resulted in an undesired calcium transient (red arrow) that was avoided at an 
injection-speed of 25 µL / s.  
 
3.3.2 Investigation of the effect of hH1R ligands on the mobilisation of 
intracellular calcium in U-373 MG cells 
 
3.3.2.1 Concentration-dependent increase in the intracellular calcium level by 
histamine 
 
Histamine increased the intracellular calcium level in a concentration-dependent manner 
when investigated in the 96-well and the 384-well format (Fig. 3.6).  
 
 
The EC50-values of histamine calculated from data collected in the two microplate formats, 
5.9 ± 0.6 µM (96-well plates) and 3.5 ± 0.4 µM (384-well plates), are in the same range and 
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Fig. 3.6: Concentration-dependent increase in the intracellular calcium level by histamine A: in 
96-well plates; B: in the 384-well format (mean values ± SEM; n = 3).  
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in agreement with data which were previously determined in our workgroup at the LS 50 B 
spectrofluorimeter: 5.4 ± 0.6 µM (Kracht, 2001). 
 
3.3.2.2  Investigation of H1R antagonists 
 
3.3.2.2.1 Optimisation of assay parameters 
 
To avoid an additional injection process, the fura-2 / AM loaded cells were pre-incubated with 
mepyramine in the 96-well plate before histamine was injected. 160 µL of the fura-2 / AM 
loaded cell suspension (1 · 106 cells / mL) and 20 μL of mepyramine (Sigma) (10-fold 
concentrated feed solutions compared to final assay concentration in PBS) were pipetted into 
the cavities of a 96-well plate. Before the 5th cycle, 10 µL of PBS were added by injector A at 
a speed of 200 μL / s in order to initialize shaking of the microplate in the well kinetic mode 
(note: the software of the GENios Pro™ reader does not enable shaking without preceding 
injection). Histamine (600 μM in PBS; 10 μL; speed injector B: 200 μL / s) was injected after 
cycle 79. To accelerate equilibration after addition of the antagonist to the fura-2 / AM loaded 
cells, the plates were shaken for 5 min per well kinetic (speed: 60 rpm, mode: orbital, settle 
time: 0 s) before the agonist was injected. This procedure revealed a concentration-
dependent decrease in the intracellular calcium level by the antagonist (Fig. 3.7). 
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Fig. 3.7: Concentration-dependent 
decrease in the calcium signal elicited 
with histamine (30 µM) by mepyramine 
(mean values ± SEM; n = 6) 
 
An IC50-value of 7.9 ± 0.7 nM was determined. The respective Kb-value was calculated 
according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973) amounting to 1.3 nM ± 
0.1 nM: Kb = IC50 · EC50 / (EC50 + [A]), where [A] represents the concentration of the agonist 
used in the assay (30 µM of histamine). The EC50 value of the agonist histamine was 
determined to be 5.9 ± 0.6 µM (cf. 3.3.2.1). 
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The Kb-value is in agreement with data (3.0 nM (Kracht, 2001)) that were previously 
determined at U-373 MG cells using the LS 50 B spectrofluorimeter. 
Attempts to increase the throughput by reducing the time required for data acquisition were 
performed according to section 3.2.5, transparent 96-well plates. Under these conditions, a 
Kb-value of 1.3 ± 0.2 nM (IC50 = 8.0 ± 1.0 nM) was calculated for mepyramine (Fig. 3.8, A). 
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Fig. 3.8: Concentration-dependent decrease in the histamine (30 µM)-induced calcium signal by 
mepyramine. A: Assay performance according to section 3.2.5; B: for specific assay conditions see 
text below. Indicated are mean values ± SEM; n = 3. 
 
Alternatively, the fura-2-loaded cells were preincubated in the 96-well-plate with mepyramine 
at various concentrations without shaking at room temperature for 15 min under light 
protection prior to the challenge with histamine (20 µL; 300 µM in PBS; Fig. 3.8, B). The 
respective Kb-value of mepyramine for this experiment without shaking was 0.5 ± 0.3 nM 
(IC50 = 3.1 ± 2.0 nM). 
The procedure without shaking of the plate was also applied to 384-well plates. Here, 
mepyramine suppressed the histamine-induced calcium signal in a concentration-dependent 
manner, too (Fig. 3.9). The corresponding Kb-value of mepyramine was determined to be 0.7 
± 0.1 nM (IC50 = 6.4 ± 0.3 nM; EC50 of histamine in the 384-well format: 3.5 ± 0.4 µM; cf. 
section 3.3.2.1). 
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Fig. 3.9: Suppression of the histamine (30 
µM)-induced calcium signal by mepyramine 
in the 384-well format (mean values ± SEM; 
n = 3).  
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The investigation of the reference H1R antagonist mepyramine in the 384-well format 
enabled the correct determination of the Kb-value and gave the most precise results 
(compare SEM in Fig. 3.9). Therefore, this experimental setup was selected for further 
investigations because of practicability and reliability. 
Final assay concentrations of DMSO up to 1 % (v/v) did not impair the appropriate 
calculation of the Kb-value of mepyramine (Fig. 3.10): 0.4 ± 0.2 nM (IC50 = 3.6 ± 2.1 nM).  
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Fig. 3.10: Competition curve of 
mepyramine in the presence of 1.0 % 
DMSO (v/v) (Mean values ± SEM; n = 
3). Calcium signals were elicited with 
30 µM of histamine. 
 
In order to determine the contribution of the injection process to the increase in the 
intracellular calcium level, the solvent of histamine (PBS) was added to the loaded cells by 
injection. The increase in the intracellular calcium level, probably due to cell rupture, was 
amounting to 3.25 % relative to the calcium transient evoked by histamine (30 µM) (Fig. 
3.11). This result was considered as a correction value for the calculation of antagonistic 
activities.  
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Fig. 3.11: Comparison of the increase in the 
intracellular calcium level in fura-2 loaded U-
373 MG cells upon injection of PBS or 
histamine, respectively. Indicated are mean 
values ± SEM, n = 6. 
 
 
In order to investigate the reliability of calcium signals with respect to the time period 
between the loading procedure with fura-2 / AM and the registration of the fluorescence (i.e. 
time period of post-incubation), the antagonistic activity of mepyramine was determined. The 
competition curve which was constructed from data calculated from 15 to 57 min after 
termination of the loading procedure (Fig. 3.12, A) revealed an antagonistic activity of 
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mepyramine (Kb-value: 0.3 ± 0.1 nM; IC50 = 2.6 ± 0.4 nM) in the same order of magnitude as 
the Kb-values calculated from samples assayed from 311 to 353 min after completion of the 
loading procedure (Fig. 3.12, B; Kb = 0.4 ± 0.1 nM; IC50 = 4.3 ± 0.8 nM).  
c (mepyramine) [nM]
0.01 0.1 1 10 100 1000
in
tra
ce
llu
la
r c
al
ci
um
 [%
]
0
20
40
60
80
100
120
c (mepyramine) [nM]
0.01 0.1 1 10 100 1000
0
20
40
60
80
100
120
 
BA 
Fig. 3.12: Investigation of the concentration-dependent decrease of the histamine-mediated calcium 
response by mepyramine at various time periods of post-incubation. A: from 15 to 57 min; B: from 311 
to 353 min. Indicated are mean values ± SEM; n = 3. 
   
3.3.2.2.2 Investigation of standard antagonists in the optimized assay  
  
Additional hH1R-antagonists were investigated in the optimized assay using 384-well plates 
(Fig. 3.13).  
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Fig. 3.13: Concentration-dependent 
decrease in the histamine-induced calcium 
response (final assay concentration of 
histamine: 30 µM) by various hH1R 
antagonists (mean values ± SEM; n = 3). 
 
 
 
For all ligands, the obtained pharmacological data are in agreement with data reported in 
literature (Table 3.3): The Kb-value calculated for (R)-(-)-dimethindene agrees to that 
determined by SEIFERT (Seifert et al., 2003). The Kb-value obtained for (R,S)-dimethindene 
is higher compared to that of the eutomer, but lower than reported for the pure distomer 
(Seifert et al., 2003). The Ki-value for (R)-(-)-cetirizine reported by GILLARD (Gillard et al., 
2002) was confirmed by a comparable Kb-value with the calcium assay in the 384-well 
format. The Kb-values determined for triprolidine and mepyramine are in the same order of 
magnitude as those reported in literature (Kracht, 2001; Seifert et al., 2003).  
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Table 3.3: Comparison of pharmacological data of reference H1R antagonists determined in the fura-2 
assay (384-well format) with results reported in literature. 
 
Ligand 
GTPase 
assay1 
Kb [nM] 
Radioligand 
binding assay2
Ki [nM] 
Fura-2 assay, 
cuvettes 
(U-373 MG cells)3
Kb [nM] 
Fura-2 assay, 
384-well format 
(U-373 MG cells) 
Kb [nM] 
(S)-(+)-dimethindene  113.2 ± 30.9 n.d. n.d. n.d. 
(R)-(-)-dimethindende  2.7 ± 1.5 n.d. n.d.        1.9 ± 0.2 
(R,S)-dimethindene  n.d. n.d. n.d.      37.1 ± 5.8 
(R)-(-)-cetirizine  n.d. 2.5-4.0 n.d.      5.5 ± 0.4 
triprolidine  4.4 ± 1.6 n.d. n.d.      0.5 ± 0.2 
mepyramine  5.7 ± 0.9 n.d. 3.0      0.7 ± 0.1 
 
 
 
 
1Seifert et al., 2003; 2Gillard et al., 2002: Ki-value was calculated from the reported mean ± S.D.  
of the pKi value; 3Kracht, 2001  
3.3.3    Screening of a library of potential H1R ligands in the microplate fura-2 
calcium assay on U-373 MG cells 
 
The appropriate performance of the assays both in the 96-well and the 384-well format for 
the investigation of compounds in duplicate was confirmed by the suppression of the 
histamine-induced calcium signal with mepyramine: 8 nM of the antagonist suppressed the 
calcium transient by approx. 50 %, whereas in the presence of 100 nM of mepyramine, only 
a slight increase in the intracellular calcium level elicited by the injection process was 
observed (Fig. 3.14 A and B). 
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Fig. 3.14: Suppression of the hH1R-mediated calcium signal elicited with histamine (30 µM) 
in U-373 MG cells by increasing concentrations of mepyramine in A: 96-well plates (n = 18 
(no antagonist) or n = 3 (8 and 100 nM of mepyramine, respectively)); B: 384-well plates (n 
= 16 (no antagonist) or n = 8 (8 and 100 nM of mepyramine, respectively)). Indicated are 
mean values ± SEM in each case.  
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The correct performance of the assays for the concentration-dependent decrease in the 
intracellular calcium level by putative hH1R-antagonists was confirmed by investigation of 
mepyramine concentrations ranging from 0.1 to 100 nM. The results for a measurement time 
of 120 cycles per well were comparable to assays performed with a reduced measurement 
time per well of 46 cycles (Fig. 3.15). 
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Fig. 3.15: Comparison of the concentration-dependent decrease in the intracellular calcium 
level (evoked with 30 µM of histamine in U-373 MG cells) by mepyramine on an assay plate 
A: measured with 120 cycles and B: determined with 46 cycles per well kinetic. Indicated 
are mean values ± SEM; n = 16 (no antagonist); n = 2 (0.1-50 nM); n = 4 (100 nM) in each 
case. 
The recording of 120 cycles per well kinetic enabled the investigation of 192 samples in one 
assay per day. However, the monitoring of 46 cycles per well kinetic in the same time period 
drastically increased the throughput to 480 samples in one assay per day.  
The screening of the compounds in the microtitre format for their antagonistic activity at the 
hH1R contributed to the identification of several lead structures which were further optimized 
by chemical modification of the respective scaffold by the coworkers of the Origenis 
company. Five of those optimized compounds (structures not disclosed due to possible 
conflict with intellectual properties) were investigated by radioligand binding experiments 
(section 3.3.4) on hH1R, hH2R, hH3R and hH4R with respect to histamine receptor subtype 
selectivity. 
 
3.3.4 Radioligand binding assays 
 
None of the 5 selected compounds did significantly displace the respective radioactive tracer 
up to a concentration of 10 µM at the human histamine receptors hH2R, hH3R or hH4R, 
respectively, indicating negligibly low affinity to histamine receptors other than hH1R. The 
antagonist controls (10 µM of famotidine at the hH2R or 10 µM of thioperamide at the hH3R 
and the hH4R, respectively) clearly decreased the binding of the respective radioligands (Fig. 
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3.16). Therefore, the performance of the assay was appropriate and the observed low affinity 
of the investigated compounds is valid. 
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Fig. 3.16: Radiochemical 
competition binding experiments on 
membranes from Sf9 insect cells 
expressing A: the hH2R; B: the hH3R 
or C: the hH4R, respectively (Mean 
values ± SEM; n = 2). Further details 
with regard to assay performance 
are summarized in section 3.2.6, 
Table. 3.2.  
 
In contrast, the investigated new chemical entities displaced [3H]-mepyramine from the hH1R. 
Compounds 1 and 3 at concentrations  ≥ 1 µM inhibited the radioligand binding by around 30 
and 50 %, respectively. Compounds 2 and 4 suppressed the binding of [3H]-mepyramine by 
nearly 90 %, whereas compound 5 almost completely displaced the radioactive tracer at 
concentrations ≥ 1 µM. The latter compound showed the highest affinity of the 5 investigated 
ligands. The antagonist control (10 µM of diphenhydramine) displaced almost completely the 
binding of the radioactive tracer which demonstrates the appropriate performance of the 
binding assay (Fig. 3.17).       
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Fig. 3.17: Competition of [3H]-
mepyramine (5 nM) by the 
investigated compounds (Mean 
values ± SEM; n = 2).  
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3.4 Summary and conclusions 
 
 
The adaptation of the fura-2 assay to the microtitre format was successful. The agonist 
histamine was appropriately characterised by a concentration-dependent increase in the 
intracellular calcium level in both the 96- and the 384-well format. For the pharmacological 
characterisation of hH1R antagonists, measurements performed in the 384-well format led to 
more reliable data than those in the 96-well format. Optimization of the conditions, especially 
sequential reduction of the measurement time, enabled the characterisation of 480 samples 
in one assay per day in the 384-well format.  
In order to prove the applicability of the developed assay for the screening of potential hH1R 
antagonists, a compound library of more than thousand new substances (cooperation with 
Origenis GmbH) was investigated in the 384-well format. Among these substances 
compound 5 was identified as a highly affinic and selective hH1R antagonist. Thus, this work 
successfully contributed to the identification of a potential drug candidate, confirming the 
prospect of the developed calcium assay in drug discovery.  
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Chapter 4 
 
Determination of ligand binding to 
the human histamine H2 receptor by 
radiochemical and fluorescence-
based methods  
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4.1 Introduction 
 
4.1.1 Investigation of HEK293 cells for the expression of human histamine 
receptors 
  
In contrast to hH1R expressing U-373 MG cells (see chapter 3), cell types which 
endogenously express the hH2R previously revealed as less appropriate for the 
establishment of cellular assays. For instance, MKN-45 cells which constitutively express the 
hH2R (Arima et al., 1991) were investigated in our workgroup for specific binding of [3H]-
tiotidine (Kracht, 2001). Unfortunately, the radioligand showed only low binding on those cells 
accompanied with a relative high extent of unspecific binding (Kracht, 2001). In addition, 
neither a histamine-mediated increase in the intracellular cAMP level (Kracht, 2001) nor in 
intracellular Ca2+ (Schneider, 2005) was detectable. Other cells which express the hH2R like 
HL-60 cells additionally express hH1 receptors (Burde and Seifert, 1996). Coexpression of 
different receptor subtypes may lead to misinterpretation of binding or functional data when 
non-selective ligands such as histamine interact with both receptor subtypes simultaneously. 
Hence, their affinity to the receptor subtype of interest could be underestimated. 
Furthermore, interacting signalling cascades would be activated by a non-selective agonist 
such as histamine. This could become especially relevant in case of the coexpression of the 
hH2R and the hH3R or hH4R, as the activation of the hH2R leads to an increase in the 
intracellular cAMP level, whereas the stimulation of both other receptor subtypes provokes 
the opposite effect. Thus, the chosen cell line should only express the histamine receptor 
subtype of interest. Due to the lack of appropriate wild-type cells expressing either the hH2R 
or the hH4R (the hH4R is preferentially expressed on immune cells which are laborious in 
view of handling, see for instance BUCKLAND (Buckland et al., 2003)), respectively, 
transfection experiments were considered most promising to establish cellular binding and 
functional assays.  
In the present work experiments were focussed on HEK293 cells, as these are well 
characterised (Thomas and Smart, 2005), can be conveniently detached (trypsinization is not 
required) and are rapidly growing. Since little information on human histamine receptor 
subtypes expressed in HEK293 cells has been available, RT-PCR was performed to 
investigate histamine receptor expression at the mRNA level. Furthermore, the potential 
expression of the hH2 receptor protein was analyzed in western blot experiments.  
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4.1.2 Stable co-expression of the human histamine H2 receptor and the 
chimeric Gαprotein qs5-HA in HEK293 cells 
 
The cDNAs encoding the proteins of interest have to be cloned in appropriate plasmids 
which enable the amplification of DNA in competent bacteria and the stable transfection of 
mammalian cells. The commercially available pcDNA3.1 vectors (Invitrogen, Karlsruhe, 
Germany) were used for those experiments. The vectors contain an ampicillin resistance for 
the propagation of DNA in bacteria and various genes according to resistances against 
G418, hygromycin B or Zeocin™, respectively (for a vector map see 4.2.2.2). As there is no 
evidence of cross-resistances between the latter antibiotics, co-transfection of mammalian 
cells using the respective DNA constructs and subsequent selection should enable the 
establishment of cells which stably express the proteins of interest. 
 
4.1.3 Determination of ligand affinity in binding assays 
  
The determination of ligand affinity with binding assays is an essential step in the scope of 
drug development and characterisation of substance libraries. Binding assays can be 
performed on membrane preparations, whole cells, solubilised receptor preparations or 
whole tissues (Hulme and Buckley, 1992). The classical approach for the determination of 
ligand affinity is the radioligand binding assay. An ideal radioligand for the performance of 
that kind of assay is a high affinity neutral antagonist (dissociant constant (Kd) in the range of 
0.01 to 1 nM) which binds in a reversible competitive manner (Hulme and Birdsall, 1992). 
Neutral antagonists are favoured compared to agonists because undesired effects like 
agonist locking (Hulme and Birdsall, 1992), dependency of binding data on G-protein status 
(Lazareno, 2001) or misinterpretations due to receptor internalization are often observed 
when using radioactive agonists for binding studies. Tritiated radioactive tracers like [3H]-
tiotidine are very useful tools as the pharmacological properties of a receptor ligand are 
usually not apparently changed by introduction of tritium in the molecule. Due to a half-life of 
approx. 12 years, corrections for decay during the lifetime of the experiment are not required 
when using tritiated compounds. The high specific activity of tritium enables an economic use 
of respective radioligands (McFarthing, 1992). In conventional radiochemical assays, bound 
and free tracer have to be separated before measurement. In addition, radioactive 
substances are hazardous, require special handling of waste, and so are expensive (Keen, 
1995; Schneider et al., 2006). The most convenient method for the separation of unbound 
from bound ligand is filtration due to its advantages compared to other separation techniques 
like centrifugation. Filtration provides high efficiency of the separation process, relative low 
complexity and time requirement, a low non-specific background due to minor radioligand 
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binding to cellular components which differ from the receptors of interest and good 
reproducibility (Wang et al., 1992).  
For the purpose of validation, a radioligand binding assay was established for HEK293-
hH2R-qs5-HA cells using the Combi Cell Harvester 11025 (Skatron, Norderstedt, Germany) 
which was kindly provided from Prof. Heilmann (Institute of Pharmacy, Department of 
Pharmaceutical Biology, University of Regensburg). As washing steps during assay 
performance could lead to the detachment of HEK293-hH2R-qs5-HA cells due to their 
relative weak adherence, assays were not performed in 24-well plates but with suspended 
cells. Samples were prepared in 96-well plates and after incubation, cells (bound 
radioactivity) were transferred row-wise onto a glass fibre filter (Fig. 4.1, A) by the shorter 
outlet tubes. Cold washing buffer (4 °C) was added through the longer inlet tubes with the 
smaller diameters (Fig. 4.1, B). Thus, separation of bound from free radioligand at the end of 
the incubation was performed by filtration. 
 
  
Fig. 4.1: The Combi Cell Harvester 11025. A: Principle: 
chilled buffer is added through the tubes to the suction 
unit and distributed into the cavities of the 96-well plate 
(red arrows) whilst the samples are harvested (blue 
arrows). The cell bound radioactivity is gathered on a 
glass fibre mat that can be fixed in the filter block and 
moved after suction of 1 row in order to enable the 
harvesting of the next row (gray arrows).  
B: The suction unit in more detail: cold buffer  
is added to the wells through the inlet tubes (red  
arrows) whilst the samples are sucked through the  
outlet tubes (blue arrows). 
B 
A 
 
In order to reduce unspecific binding of the radioactive tracer ([3H]-tiotidine) to the glass fibre 
mat (negatively charged at pH 7.4), the negative charges of the filter were compensated by 
pre-treatment with the polycation polyethylenimine (PEI). 
After a washing step to remove excessive radioligand, the filter mat was moved to the next 
position. The filter discs are transferred to scintillation vials and analyzed by liquid scintillation 
counting.   
The determination of ligand affinity with fluorescence-based methods is a promising 
alternative to radiochemical binding assays. Flow cytometric measurements with 
fluorescence-labelled ligands addressing the respective receptor are of special interest 
because binding data can be determined under equilibrium conditions without washing steps. 
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The receptor-expressing cells pass through laser beams in a thin sample stream which is 
hydrodynamically focused in the surrounding sheath fluid. As the laser beam is precisely 
directed towards the surfaces of the cells, it is mainly cell-associated fluorescence that is 
detected. Hence, the signal is hardly impaired by free fluorescent ligand in solution (Bohn, 
1980; Schneider et al., 2006). Advances in sample delivery systems make flow cytometry 
also applicable to the requirements of high throughput screening (Edwards et al., 2004; 
Kuckuck et al., 2001; Ramirez et al., 2003; Young et al., 2009). In addition, flow cytometry 
provides the occasion to determine multiple parameters in only one sample (Schneider et al., 
2006).  
 
 
 
 
 Chapter 4.2  56 
4.2 Materials and methods 
 
4.2.1 Investigation of HEK293 cells for the expression of human histamine 
receptors 
 
4.2.1.1 Expression analysis of human histamine receptors in HEK293 cells at the 
mRNA level 
 
4.2.1.1.1 Cell culture 
 
HEK293 cells (Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ), 
Braunschweig, Germany) were maintained in DMEM (Sigma, Deisenhofen, Germany) 
supplemented with 10 % FBS. Cells were passaged 1:10 twice a week without trypsinization. 
Cells were grown to approx. 90 % confluency in a 75-cm2 culture flask prior to the isolation of 
total mRNA. 
 
4.2.1.1.2 Isolation of total mRNA from HEK293 cells 
 
The isolation of RNA was performed with the RNeasy Kit (Qiagen, Hilden, Germany) 
according to the manufacturer´s instruction "Isolation of RNA from animal cells, spin column 
method". In order to avoid overloading of the spin column, approx. 1·106 cells were 
processed per spin column. Isolated mRNA was stored at -80 °C until use.    
 
4.2.1.1.3 Determination of mRNA concentration 
 
Isolated mRNA was diluted 1:50 with RNAse-free water from the RNeasy Kit and analyzed 
by UV spectrometry at 260 nm: c (RNA) [µg / mL] = 50 · 40 · A260.  
 
4.2.1.1.4 Synthesis of cDNA by reverse transcription (RT) and amplification by polymerase 
chain reaction (PCR) 
  
RT was performed according to SCHNEIDER (Schneider, 2005): 1 µg of total mRNA and 1 
µL of an oligo(dT12) primer solution (100 µM; MWG, Ebersberg, Germany) were diluted to 10 
µL with RNAse-free water. The mixture was heated at 70 °C for 5 min and cooled down to 4 
°C with the Master Cycler (Eppendorf, Hamburg, Germany). 1 µL of M-MLV reverse 
transcriptase (Invitrogen, Karlsruhe, Germany), 2 µL of a dNTPmix (2 mM; MBI Fermentas, 
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St. Leon-Rot, Germany), 4 µL of 5x first strand buffer (Invitrogen) and 2 µL of DTT (Roche, 
Basel, Switzerland) were added. The sample was diluted to 20 µL with RNAse-free water. 
Snythesis of cDNA and amplification by PCR was performed with the Master Cycler: reverse 
transcription was accomplished at 37 °C for 1 h. Thereafter, the enzyme was inactivated at 
95 °C for 2 min. Samples were stored at -20 °C. 
PCR samples were prepared by mixing 2 µL of cDNA, 8 µL of Millipore water, 8 µL of Master 
Mix (Eppendorf) and 2 µL of the primer pair for the amplification of the respective human 
histamine receptor subtype (1 µL of the sense and the antisense primer in each case, 1 µM; 
MWG).  
As a control for the successful isolation of the mRNA, a sample was prepared with a primer 
pair that enables the amplification of the sequence of β-actin: 1 µL of each primer was used 
(1 µM; MWG). 
Two plasmids comprising hH3R or hH4R cDNA, respectively, were kindly provided by David 
Schnell (Institute of Pharmacy, Department of Pharmacology and Toxicology, Regensburg) 
and were used as controls for the suitability of the PCR conditions. Instead of 2 µL of cDNA 
solution, 2 µL of the respective plasmid (10 µg / mL) were used. In case of the hH1R and the 
hH2R, primer pairs were used, previously proven to give reproducible results under the 
chosen PCR conditions (Schneider, 2005). Primers, lengths of amplification products and 
positive controls are summarised in table 4.1. 
 
Table 4.1: PCR analysis of histamine receptor expression in HEK293 cells. Overview about used 
primers, product lengths and positive controls. 
 
gene sense primer antisense primer 
product 
length 
[bp] 
positive 
control 
hH1R 
5’-GGT GCT GTA TGC CGT 
ACG GA-3’ 
5’-TGG ACA GAG CGG 
TAG CGA TCA-3’ 229 - 
hH2R 
5’-CCA TCA GGG AGC ACA 
AAG CC-3’ 
5’-TTC TGT CCC ACT 
CCA CAC CTG G-3’ 370 - 
hH3R 
5’-GAC GAT GAT GAC GCC 
ATG GAG CGC GCG CCG 
CC-3’ 
5’-GAT CCT CTA GAT 
TAG TGA TGG TGA TGA 
TGG TGC TTC CAG CAG 
TGC TC-3’ 
 
1382 
 
pVL1392-
SF-hH3R 
hH4R 
5’-GAC GAT GAT GAC GCC 
ATG CCA GAT ACT AAT 
AG-3’ 
5’-GAT CCT CTA GAT 
TAG TGA TGG TGA TGA 
TGG TGA GAA GAT ACT 
GAC CG-3’ 
 
1217 
 
pGEM-3Z-
SF-hH4R 
β-
actin 
5’-CGG GAT CCC CAA CTG 
GGA C-3’ 
5’-GGA ATT CTG GCG 
TGA GGG A-3’ 304 - 
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PCR was performed under the following conditions (Schneider, 2005): 
 
(1) initial denaturation: 95 °C, 120 s 
 (2) denaturation:  95 °C,   30 s 
 (3) annealing:  60 °C,   60 s 
 (4) extension:  72 °C,   30 s 
   (5) hold:  4 °C 
  
Steps (2)-(4) were repeated 34 times. Samples were subsequently stored at -20 °C. 
 
4.2.1.1.5 Agarose gel electrophoresis 
 
Analysis by agarose gel electrophoresis was performed according to SCHNEIDER 
(Schneider, 2005) with minor modifications: 5x TBE buffer was prepared by dissolving 445 
mM of tris base (USB, Cleveland, USA), 445 mM of boric acid (Merck, Darmstadt, Germany) 
and 10 mM of Titriplex® III (Merck) in Millipore water.  1x TBE buffer was prepared by dilution 
of the respective stock solution (5x) with Millipore water. 0.75 g of agarose (pegGOLD 
Universal-Agarose; Peqlab, Erlangen Germany) were dissolved in 50 mL of 1x TBE buffer 
with heating and continuous stirring.  
2 µL of an aqueous ethidium bromide solution (10 mg / mL; Janssen Chimica, Beerse, 
Belgium) were added. The solution was poured into the gel chamber of the PerfectBlueTM 
Mini S gel system (Peqlab). In order to create pockets for the application of the samples, 2 
combs were adjusted into the solution. After solidification, the gel was covered with the 1x 
TBE buffer, and the combs were carefully removed. 10 µL of each PCR sample were mixed 
with 2 µL of 6x loading dye solution (MBI Fermentas). 5 µL of each mixture were added per 
pocket of the gel. 5 µL of the Mass Ruler DNA Ladder mix, ready to use (MBI Fermentas) 
were used for reference (grading: 80, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1031, 
1500, 2000, 2500, 3000, 4000, 5000, 6000, 8000 and 10000 bp). 
The voltage was set to 90 V during a gel running time of approx. 90 min. The gels were 
analysed by transillumination at 254 nm (Gel Doc 2000; Bio-Rad Laboratories, Munich, 
Germany) using the Quantity One software (Bio-Rad Laboratories).   
 
4.2.1.2 Western blot analysis of the hH2R expression 
 
4.2.1.2.1 Cell culture and membrane preparation 
 
HEK293 and HEK293 T cells, which express the SV-40 large T-antigen (Wurm and Bernard, 
1999), were cultured as described in 4.2.1.1.1. HL-60 HD cells (HD is an abbreviation for 
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Heidelberg, Germany) were obtained from the Department of Pharmacology and Toxicology, 
University of Regensburg, and maintained in RPMI 1640 medium (Sigma) including 10 % 
FBS. This cell type emerged from HL-60 cells which were obtained from the American Type 
Culture Collection. In contrast to the latter cell type, calcium transients upon H2R stimulation 
can be more readily monitored in HL-60 HD cells. The reason for this observation is not 
elucidated yet. Furthermore, it is neither known, how HL-60 HD cells emerged from HL-60 
cells, nor in what respect both cell types differ on the molecular level (Prof. Dr. Roland 
Seifert, Institute of Pharmacology, Medical School of Hannover, Germany, 2009, personal 
communication). 
HEK293 and HEK293 T cells were seeded in sixteen 175-cm2 culture flasks (Nunc) in each 
case and grown to confluency within 1 week (approx. 5 · 106 cells were seeded per flask). 
Membranes were essentially prepared according to MAYER (Mayer, 2002): briefly, washing 
steps with the homogenizing buffer prior to the detachment of the cells were omitted due to 
the weak adherence of both investigated cell types. Cells of four 175-cm2 flasks were 
harvested in portions with homogenizing buffer at 4 °C. Cells were disrupted in a Potter-
Elvejham-homogenizer (B. Braun Melsungen, Melsungen, Germany) by 10 strokes at 1500 
rpm on ice (30 s break after 5 strokes) and subsequently centrifuged for 5 min at 650 g. The 
supernatant was centrifuged at 40000 g for 30 min. The resulting pellet was washed with 
homogenizing buffer and centrifuged again at 40000 g for 30 min. The pellet was re-
suspended in 1000 µL of homogenizing buffer by a 1 mL syringe with a 0.4 x 20 mm needle. 
The amount of membrane protein was determined according to Bradford by 1:5 dilution of 
the Bio-Rad protein assay dye reagent concentrate (Bio-Rad Laboratories). Membranes 
were frozen in liquid nitrogen and stored at -80 °C.  
In case of HL-60 HD cells, four 175-cm2 culture flasks were grown to confluency within 4 
days (approx. 5 · 106 cells were seeded per flask, the final volume in each flask was 50 mL). 
HL-60 HD cells, which grow in suspension, were collected in 50 mL tubes and centrifuged for 
5 min at 300 g. The cell pellet was resuspended in homogenizing buffer and then handled as 
described for HEK293 and HEK293 T cells.  
 
4.2.1.2.2 Investigation of membranes from mammalian cells in semi-dry western blots 
 
For the preparation of a 2-fold concentrated electrophoresis buffer, 28.8 g of urea were 
dissolved under heating in approx. 20 mL of Millipore water. The solution was cooled to room 
temperature and 1.5 g of SDS, 1.8 g of dithiothreitole, 1.5 mL of Tris-base (1M, pH 8.0;), 6.0 
mL of glycerol (50 % (v/v)) and 6.0 mg of bromophenol blue were added and dissolved. The 
solution was filled up with Millipore water at 27.0 mL. The buffer was aliquoted and stored at 
-20 °C (all chemicals used for the preparation of the buffer were from Merck).  
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As positive and negative controls, membranes from Sf9 cells, either expressing the hH2R or 
the hH1R and RGS4, respectively, were provided by the Department of Pharmacology and 
Toxicology, University of Regensburg.  Every sample contained 15 µg of membrane protein. 
Discontinuous SDS-PAGE was performed according to HOFINGER (Hofinger, 2007). 
Samples were diluted with the electrophoresis buffer, heated for 3 min at 100 °C and pipetted 
in the gel pockets. Semi-dry western blots were essentially performed as described 
previously (Hofinger, 2007). The anti-FLAG primary antibody (4.5 mg protein / mL; M1, 
monoclonal antibody, Sigma) and the secondary antibody (biotinylated anti-mouse / rabbit 
IgG; Vector Laboratories, Burlingame, USA) were diluted 1:1000 with PBS including Tween 
20 (0.05 % (v/v); Tween 20 was from Roth, Karlsruhe, Germany) prior to use. The membrane 
with the blotted proteins was incubated both with the primary and the secondary antibody for 
2 h. Visualization, further handling of the membrane and data analysis were performed as 
described previously (Hofinger, 2007). Briefly, after washing, the membrane was incubated 
with a biotin / avidin / horseradish peroxidase (HRP) reaction kit (VECTASTAIN® ABC-kit 
Standard, Vector laboratories, Burlingame, USA), which was prepared 30 min before the use 
according to the manufacturer’s instructions. Alternatively, a secondary antibody, which is 
linked to horseradish peroxidase (sheep anti-mouse IgG coupled to peroxidase; Amersham 
Biosciences, Freiburg, Germany; the antibody was provided by the Department of 
Pharmacology and Toxicology, University of Regensburg), was used for visualization in a 
dilution of 1:1000 with PBS including Tween 20 (0.05 % (v/v)). Readout was performed with 
the diaminobenzidine (DAB) staining solution according to the manufacturer’s instruction 
(DAB Kit, Vector Laboratories). Brown bands appeared after 5-10 min. Excessive substrate 
was removed by washing with water and the dry membrane was scanned with a DAB / HRP 
filter on the Bio-Rad gel detection system (GS-710 Imaging Densitometer) using the Quantity 
One software (version 4.0.3, Bio-Rad Laboratories). 
 
4.2.1.2.3 Investigation of membranes from mammalian cells in wet western blots 
 
Separation gels containing 12 % of acrylamide (v/v) were prepared by mixing 2.2 mL of 
Millipore water, 2 mL of buffer A (18.17 g of Tris base and 4.0 mL of SDS 10 % (w/v) ad 
100.0 mL of Millipore water, pH 8.8), 3.2 mL of acrylamide / bisacrylamide (30 % solution, 
acrylamide / bisacrylamide = 29 / 1; Sigma) and 0.53 mL of glycerol 50 % (v/v). 
Polymerization was initialized by addition of 3.35 µL of TEMED and 33.35 µL of APS 10 % 
(v/v) (TEMED and APS were from Serva, Heidelberg, Germany). The solution was poured 
into the gel chamber and isobutyl alcohol (Merck) was added in order to smooth the 
emerging separation gel. After 45 min, the alcohol was discarded and the stacking gel was 
prepared: 3.25 mL of Millipore water were mixed with 2.5 mL of buffer B (6.0 g of Tris base 
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and 4.0 mL of SDS 10 % (w/v) ad 100.0 mL of Millipore water, pH 6.8) and 1 mL of 
acrylamide / bisacrylamide. Polymerization was started with 3.35 µL of TEMED and 50 µL of 
APS 10 % (v/v). The mixture was poured on the separation gel. Gel pockets were prepared 
by addition of suited combs to the stacking gel. After another 45 min, the gel was stored at 4 
°C or directly used for gel electrophoresis. The stacking gel contained 3 % of acrylamide 
(v/v). 
Samples were prepared according to 4.2.1.2.2 and separated in a Mini Protean II 
Electrophoresis Cell (Bio-Rad Laboratories) for 150 min at room temperature (110 V). For 
reference, 5 µL of the Precision Plus Protein™ pre-stained standard, dual color (Bio-Rad 
Laboratories) were used (grading: 20, 25, 37, 50, 75, 100, 150, 250 kDa). The running buffer 
used for electrophoresis was prepared by 1:10 dilution of a 10-fold concentrated stock 
solution containing 30 g of Tris base, 144 g of glycine (Merck) and 10 g of SDS in 1000 mL of 
Millipore water, pH 8.3.  
Separated proteins were blotted by the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad Laboratories): 4 layers of filter paper, 2 glass fibre mats and 1 nitrocellulose-membrane 
(0.45 µm) were equilibrated for 5 min in the blotting buffer containing 14 g of glycine, 3 g of 
Tris base, 800 mL of Millipore water and 200 mL of methanol. The gel and the membrane 
were enclosed by 2 layers of filter paper and 1 glass fibre mat on each side. Transfer of 
separated proteins to the membrane was realized for 120 min at 4 °C (0.15 A).   
In order to suppress unspecific binding of the antibodies, the membrane was subsequently 
incubated in a 5 % (w/v) mixture of fat-free milk (Saliter, Obergünzburg, Germany) in TBS 
including 0.1 % of Tween 20 for 2 h. TBS buffer was prepared by 1:10 dilution of a 10x buffer 
containing 80 g of NaCl (Merck) and 24.23 g of Tris-base in 1000 mL Millipore water, pH 7.6. 
The membrane was washed twice for 5 min in TBS including 0.1 % of Tween 20 (v/v). 
Primary antibodies were diluted 1:1000 in fat-free milk, Tween 20 and TBS (composition 
according to the step for the suppression of unspecific binding). The membrane was 
incubated with the mixture containing the primary antibody at 4 °C without shaking for 3 h 
(section 4.3.1.2.2) or overnight (section 4.3.1.2.1), respectively.  
The membrane was washed three times with Tween 20 / TBS 0.1 % (v/v) and incubated with 
the secondary antibody linked to horseradish peroxidase described in 4.2.1.2.2 (diluted in the 
same manner as described for the primary antibodies) for another hour at room temperature 
under continuous shaking. The membrane was again washed three times with Tween 20 / 
TBS 0.1 % (v/v) and analyzed by enhanced chemoluminescence according to the 
manufacturers instructions (Pierce, Rockford, USA).  
In addition to the anti-FLAG primary antibody and the respective peroxidase-linked 
secondary antibody, a rabbit anti-hH2R primary antibody (Biozol, Eching, Germany) and a 
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suited secondary antibody (donkey anti-rabbit IgG coupled to peroxidase, Amersham 
Biosciences, Freiburg, Germany) were used for the investigations. 
 
4.2.2 Stable co-expression of the human histamine H2 receptor and the 
chimeric Gαprotein qs5-HA in HEK293 cells 
 
4.2.2.1 Cloning, propagation and characterisation of DNA 
 
4.2.2.1.1 PCR and product purification 
 
Samples for PCR were prepared in a final volume of 200 µL containing 10 µL of each primer 
(10 µM in each case; MWG, Ebersberg, Germany), 200 ng of template, 28 µL of MgSO4 (25 
mM; MBI Fermentas), 20 µL of Pfu-buffer (10x, MBI Fermentas), 20 µL of DMSO, 20 µL of 
dNTP mix (2 mM, MBI Fermentas), 2 µL of Pfu-Polymerase (2.5 U / µL; MBI Fermentas) and 
Millipore water as required.  
PCR reactions were performed according to the following conditions: 
    
(1) initial denaturation:  95 °C, 180 s 
(2) denaturation:  95 °C,   60 s 
(3) annealing:   65 °C, 120 s 
(4) extension:   72 °C, 120 s 
(5) final extension:   72 °C, 300 s 
(6) hold:      4 °C 
steps (2)-(4) were repeated 24 times 
 
PCR products were stored at -20 °C or mixed with 40 µL of loading-dye solution (6x, MBI 
Fermentas) and separated by agarose gel electrophoresis at 90 V for approx. 1 h. 
Agarose gels were prepared according to 4.2.1.1.5 with minor modifications: Instead of 0.5 g 
of agarose, 1.0 g of agarose leading to a final gel concentration of 2 % (w/v) was used. 
Furthermore, the TBE buffer described in 4.2.1.1.5 was replaced by a TAE buffer containing 
4.84 g of Tris Base (USB), 1.142 mL of glacial acetic acid (Merck), 2 mL of EDTA solution  
(0.5 M, pH 8.0; EDTA was obtained as Titriplex III from Merck) up to 1000 mL of Millipore 
water. After separation, signals of DNA were detected by UV light (254 nm) and excised with 
a clean, sharp scalpel. DNA was extracted from the agarose gel with the Qia quick Gel 
extraction Kit (Qiagen) according to the manufacturer’s instructions. Extracted DNA was 
stored at -20 °C or directly used for digestion by restriction enzymes. 
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4.2.2.1.2 Digestion of DNA by restriction enzymes and dephosphorylation of the plasmid 
 
DNA extracted from PCR samples was concentrated to a final volume of approx. 15 µL by 
the Savant Speed Vac® Plus SC 110A (Global Medical Instrumentation, Ramsey, USA) at 
low speed. Samples were prepared according to a final volume of 50 µL by addition of 5 µL 
of 10x Tango® buffer (MBI Fermentas) or 10x buffer R (MBI Fermentas), 40-80 U of the 
respective restriction enzymes (HindIII and XhoI were from MBI Fermentas whereas ApaI 
was obtained from GE Healthcare, Freiburg, Germany) and Millipore water as required. 
Digestions were performed for 1 h at 37 °C. Samples were stored at -20 °C or directly used 
for ligation. 2.0 µL of plasmid DNA (1 µg / µL) were mixed with 1.5 µL of 10x Tango® buffer or 
buffer R, respectively. 20-40 U of restriction enzymes and Millipore water as required were 
added. Digestions were performed over a time period of 2 h at 37 °C. In order to avoid a 
possible self-ligation of the digested plasmid, 1.1 µL of a calf intestinal phosphorylase (0.1 U 
/ µL; Boehringer Mannheim, Mannheim, Germany) were added, resulting in a concentration 
of 0.05 U of phosphorylase per pmol DNA-end. 
After an additional incubation period of 1 h at 37 °C, the sample was heated at 80 °C for 20 
min in order to inactivate the phosphorylase. Samples were stored at -20 °C or directly used 
for ligation experiments.  
 
4.2.2.1.3 Ligation of DNA fragments 
 
Separation of the DNA fragments was performed by agarose gel electrophoresis (see section 
4.2.1.1.5). Recovery and purification of the respective DNA fragments were performed 
according to section 4.2.2.1.1. 
For ligation, the amount of DNA was assessed in the scope of an agarose gel analysis by 
comparing the signals of the samples with the intensity of the DNA fragments of the marker. 
Approx. 25 ng of the digested, dephosphorylated vector and 24.5 ng of the digested insert 
were used for the preparation of the ligation sample according to a 5-fold excess of the insert 
over the vector with regard to molar amounts.  
Millipore water required to achieve a final volume of 17 µL was added. The sample was 
heated for 5 min at 45 °C in order to dissolve dimers.  
2 µL of T4-DNA-ligase buffer (10x, including 10 mM of ATP; New England Biolabs, Ipswich 
Massachusetts, USA) and 1 µL of T4-DNA-ligase (1 Weiss-U / µL; New England Biolabs) 
were added. Incubation was performed at room temperature overnight. After the incubation, 
the sample was heated at 65 °C for 10 min in order to inactivate the ligase. Samples were 
stored at -20 °C or directly used for transformation of competent bacteria. 
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4.2.2.1.4 Preparation of media and agar plates 
  
For the preparation of LB medium, 10 g of bacto tryptone (Difco, Detroit, USA), 5 g of yeast-
extract (Roth) and 10 g of NaCl (Merck) were dissolved to 1000 mL of Millipore water, pH 
7.5. The solution was autoclaved at 121 °C and stored at 4 °C. 
Selective LB medium was prepared by addition of ampicillin (Sigma) to LB medium under 
sterile conditions according to a final concentration of 100 µg / mL. 
For the preparation of selective agar plates, 15 g of agar-agar (Roth) were added to 1 L of LB 
medium without antibiotic. The suspension was continuously stirred and heated for approx. 
2 h in order to dissolve the agar-agar. The solution was autoclaved and cooled to 55 °C. 
Ampicillin was added to a final concentration of 100 µg / mL under sterile conditions. 
The solution was immediately poured into the bottom-parts of culture plates (diameter: 9 cm) 
under sterile conditions. After solidification, the plates were stored at 4 °C. 
SOC medium was prepared by dissolving 2 g of bacto tryptone, 0,5 g of yeast-extract, 50 mg 
of NaCl, 1 mL of KCl (0,25 M), 0,5 mL of MgCl2 (2 M) in 100 mL of Millipore water. The 
solution was autoclaved and cooled on room temperature. Finally, 2 mL of glucose (1 M) 
were added under sterile conditions (KCl, MgCl2 and glucose were from Merck).  
SOC medium was stored at 4 °C. 
 
4.2.2.1.5 Preparation of competent bacteria 
 
Competent bacteria were prepared by analogy with a previously described procedure 
(Hofinger, 2007): 10 µL of E. coli TOP10 bacteria suspension (Invitrogen) were added to 10 
mL of LB medium under sterile conditions and cultured overnight at 37 °C and 200 rpm. 
Next day, 200 mL of LB medium were inoculated with 2 mL of the overnight culture and 
incubated at 37 °C and 200 rpm until an OD600 of approx. 0.2 was achieved (4 h). 
Then, the suspension was aliquoted into 4 polypropylene tubes (50 mL) and stored on ice for 
10 min. Subsequently, bacteria were centrifuged for 7 min at 1500 g and 4 °C. The 
supernatant was discarded under sterile conditions and 8 mL of an ice-cold CaCl2-solution 
(pH 7.0) containing 60 mM of CaCl2, 15 % of glycerol and 10 mM of PIPES (Gerbu, Gaiberg, 
Germany) were added to each tube. The bacterial pellets were resuspended and then stored 
on ice for 30 min. The samples were centrifuged for 5 min at 1000 g. The supernatant was 
discarded and each pellet was resuspended in 1.6 mL of ice-cold CaCl2-solution. 
The samples were aliquoted under sterile conditions to autoclaved 1.5 mL microfuge tubes 
corresponding to 100 µL per tube. The samples were stored for another 2 h on ice. Finally, 
bacteria were frozen in liquid nitrogen and stored at -80 °C. 
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4.2.2.1.6 Transformation of bacteria 
 
Competent bacteria were thawed on ice and approx. 10 ng of plasmid-DNA were added to 
100 µL of suspension after 10 min. The mixture was incubated for 30 min on ice. The 
suspension was heated at 42 °C for 60 s and afterwards cooled on ice for 3 min. 900 µL of 
SOC medium were added and the mixture was incubated at 37 °C and continuous shaking 
(200 rpm) for 1 h. 100 µL of the suspension were plated on an ampicillin containing agar 
plate. The rest of the suspension (900 µL) was centrifuged at 3000 rpm for 5 min. 800 µL of 
the supernatant were discarded. The pellet was resuspended in the residual volume of 100 
µL and plated on another selective agar-plate. The agar-plates were incubated overnight at 
37 °C. The plates with grown bacteria were stored at 4 °C for up to 4 weeks.   
 
4.2.2.1.7 Investigation of clones by colony-PCR 
 
Colonies were investigated according to a previously described protocol (Hofinger, 2007) 
with minor modifications: Briefly, colonies were picked with a sterile pipet tip. 1 mL of 
ampicillin containing LB medium were inoculated with the colony in a sterile reaction vessel 
and incubated for 5 h at 37 °C under continuous shaking (200 rpm). An ampicillin containing 
agar-plate was inoculated with the pipet tip that was used for the picking of the colony, 
incubated overnight at 37 °C and finally stored at 4 °C. 
After incubation for 3 min, the bacterial suspension was centrifuged at 6000 rpm. The 
supernatant was discarded and the pellet was resuspended in 50 µL of Millipore water. The 
sample was incubated at 100 °C for 5 min. Then, 10 µL of the sample were mixed with each 
0.5 µL of the primers (10 µM in each case) used for the cloning of the respective cDNA, 2 µL 
of dNTP-mix (2 mM), 2 µL of Taq-reaction-buffer including 15 mM of MgCl2 (10x, Qiagen), 
4.8 µL of Millipore water and 0.2 µL of Taq-polymerase (5 U / µL, Qiagen). For reference, the 
template of the PCR (pcDNA3.0-Neo-FLAG-hH2R-His6 or pcDNA3.1(+)-Hygro-qi5-HA, 
respectively; see also sections 4.2.2.2 and 4.2.2.3) was used: 2 µL of a solution that 
contained 10 ng of the DNA-construct / µL were diluted with 8 µL of Millipore water and 
further processed as described for the sample of the colony. Samples were amplified 
according to HOFINGER (Hofinger, 2007) and subsequently separated by agarose gel 
electrophoresis. Data analysis was performed as described in section 4.2.1.1.5. Colonies 
which were identified to incorporate the DNA of interest were chosen for further amplification 
and processed in the Maxi-Prep.      
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4.2.2.1.8 Colony amplification, glycerol culture and preparation of plasmid DNA (Maxi-Prep) 
  
The colony of interest was picked with a sterile pipet tip. Approx. 200 mL of LB medium 
containing ampicillin (100 µg / mL) were inoculated with the bacteria. The suspension was 
grown overnight at 37 °C and 200 rpm in a 500 mL Erlenmeyer flask. 700 µL of the overnight 
culture were mixed with 300 µL of a 50 % (v/v) glycerol solution in a 1.5 mL microfuge tube 
and stored at -80 °C.  The preparation of plasmid DNA from the rest of the overnight culture 
was performed with the Plasmid Purification Kit (Qiagen) according to the manufacturer’s 
instructions. 
 
4.2.2.1.9 Determination of DNA concentration and sequencing 
 
Maxi-Prep DNA was diluted 1:50 with Millipore water. The DNA concentration was 
determined by UV spectroscopy according to the following equation: 
c [µg / mL] = 50 · (70 · A260 - 40 · A280). 
Sequencing of Maxi-Prep DNA was performed by Entelechon (Regensburg, Germany). 
 
4.2.2.2 Subcloning of the hH2R 
 
The previously described vector pcDNA3.0-Neo-FLAG-hH2R-His6 (Schneider, 2005) was 
used as template for the PCR.  
In order to increase the protein expression in mammalian cells, a Kozak consensus-
sequence (Kozak, 2002) was integrated in the sense-primer: for suited annealing properties 
of the primers, the letters ATT were incorporated before the start codon ATG. As the first 
triplet after the ATG begins with a G, the common sequence of such a consensus-sequence 
(bold letters) is realized: G/A NN ATG G (Kozak, 1987), where N represents variable bases. 
Furthermore, a recognition site for HindIII (AAGCTT) and an overhang (lower case letters) in 
order to ensure appropriate cleavage by the restriction enzyme were included in the sense 
primer. In addition, the primer incorporated the 18 bases encoding the first 6 amino acids of 
the receptor (counted from ATG). The antisense primer consists of an overhang (lower case 
letters), a recognition site for the restriction enzyme XhoI (CTCGAG) and the last 21 bases of 
the receptor cDNA: 
 
sense:  5’-gcgcgAAGCTTATTATGGCACCCAATGGCACA-3’ 
antisense:  5’-atataCTCGAGTTACCTGTCTGTGGCTCCCTG-3’ 
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Both primers were created in the way that bases encoding the FLAG epitope and the 
hexahistidine tag were not amplified by PCR (Fig. 4.2). 
  
 
hH R sense-primer hexahistidine tag 2
 
 
 
 
 
 
 
 
 
The PCR was performed according to 4.2.2.1.1 and led to the signal with the expected size 
of 1095 bp (Fig. 4.3). 
1500 bp1095 bp
1031 bp
2000 bp
BA
 
 
The PCR product was purified as described in 4.2.2.1.1. The purified DNA was digested with 
the enzymes HindIII and XhoI (40 U in 50 µL in each case) in presence of buffer R and 
purified according to 4.2.2.1.2. As vector for the incorporation of the digested and purified 
insert, the vector pcDNA3.1(+)-Neo (Invitrogen) was chosen: it was digested with the same 
restriction enzymes (20 U in 20 µL in each case) and the same buffer as the insert. The 
digested vector was purified and dephosphorylated as explained in 4.2.2.1.2. 
Ligation of insert and vector was performed according to 4.2.2.1.3. Transformation, colony-
PCR, colony-propagation, isolation and characterisation of plasmid DNA was performed 
according to the sections 4.2.2.1.6 to 4.2.2.1.9.  
One conservative mutation was detected by sequencing at position 1041 (counted from the 
start-codon ATG): G1041T. 
 
Fig. 4.2: Structure of the hH2R gene construct, inserted into the pcDNA3.0-Neo-FLAG-hH2R-
His6 plasmid, and annealing points of the primers (red arrows; according to (Schneider, 
2005)). 
Fig. 4.3: Agarose gel analysis of the PCR-
product. A: HindIII-hH2R-XhoI B: Marker 
5’      3’ 
antisense-primer 
FLAG  Signal  
epitope peptide 
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Fig. 4.4:  Insertion of the gene 
for the hH2R in pcDNA3.1(+)-
Neo via the HindIII (5’) and 
XhoI (3’) restriction sites.  
 
  pcDNA3.1(+) 
  5428 bp 
 
HindIII-hH2R-XhoI 
 
4.2.2.3 Subcloning of qs5-HA 
 
The pcDNA1-qi5-HA vector was a generous gift from Prof. Dr. Bruce R. Conklin, Gladstone 
Institute of Cardiovascular Disease, University of California, San Francisco, USA. It was 
previously subcloned in the pcDNA3.1(+)-Hygro vector in our workgroup (Ziemek et al., 
2006). In order to redirect the stimulation of the hH2R by an agonist to an increase in the 
intracellular calcium level, the cDNA encoding qi5-HA had to be converted into the respective 
cDNA encoding the chimeric G-protein appropriate for a Gs-coupled GPCR, i.e. qs5-HA 
(Conklin et al., 1996; Conklin et al., 1993; Wood et al., 2000).  
Therefore, the bases encoding the five C-terminal amino acids of qi5-HA were replaced with 
those of qs5-HA by site-directed mutagenesis. A sense primer was created for the 
introduction of an overhang (lower case letters) and the recognition site of the restriction 
enzyme HindIII (AAGCTT). Furthermore, the 18 bases encoding the first 6 amino acids of the 
chimera qi5-HA (these are in agreement with those of qs5-HA) were incorporated into the 
primer. The antisense primer incorporates an overhang (lower case letters), the recognition 
site of the restriction enzyme ApaI (GGGCCC), the stop codon (TTA), the 15 bases encoding 
the 5 amino acids to be replaced (italics) and the 15 bases of the cDNA encoding the amino 
acids -6 to -11 of qi5-HA. 
 
sense:  5’- gcgcgAAGCTTATGACTCTGGAGTCCATC-3’ 
antisense: 5’- atataGGGCCCTTAGAGTAGTTCGTATTGCTTAAGGTTCAGCTGCAG-3’ 
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Hence, the bases encoding the C-terminal pentapeptide of qi5-HA (DCGLF) are not amplified 
whereas those encoding the 5 C-terminal amino acids of qs5-HA (QYELL) are incorporated 
by PCR (Fig. 4.5, (Conklin et al., 1993)) 
 
DCGLFq-backbone
qi5-HA
STOP
ApaI over-hang
QYELL
HindIII
over-hang
sense-primer
antisense-primer
5' 3'
 
 
Fig. 4.5: Principle of the site-directed mutagenesis of qi5-HA to qs5-HA.  
 
The PCR was performed according to 4.2.2.1.1 and led to a single signal with the expected 
size of 1102 bp (Fig. 4.6). 
 
B A 
1102 
1031 
1500 
Fig. 4.6: Agarose gel analysis of the PCR-
product. A: Marker  B: HindIII-qs5-HA-ApaI  
         
 
The PCR product was purified as described in 4.2.2.1.1. The purified DNA was digested with 
the enzymes HindIII and ApaI (40 U or 80 U in 50 µL, respectively) in presence of Tango® 
buffer and purified according to 4.2.2.1.2. As vector for the incorporation of the digested and 
purified insert, the vector pcDNA3.1(+)-Hygro (Invitrogen) was chosen: it was digested with 
the same restriction enzymes (20 U of HindIII and 40 U of ApaI in 20 µL) and the same buffer 
as the insert. The digested vector was purified and dephosphorylated as explained in 
4.2.2.1.2. Ligation of insert and vector was performed according to 4.2.2.1.3. Transformation, 
colony-PCR, colony-propagation, isolation and characterisation of plasmid DNA was 
performed according to the sections 4.2.2.1.6 to 4.2.2.1.9.  
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Eight conservative mutations were detected by comparison of the sequencing result with the 
theoretical sequence: G144A, A157T, G158C, C159G, G288A, G1059T, G1071A, G1074A 
(counted from the start codon ATG). The five conservative mutations mentioned first were 
already reported by ZIEMEK (Ziemek, 2006). The conservative mutations in position 1071 
and 1074 were introduced into the antisense-primer in order to improve its annealing 
properties. The conservative mutation in position 1059 is due to the difference between the 
template of the PCR, the cDNA of qi5-HA, and the cDNA of qs5-HA in that position. 
 
4.2.2.4 Transfection experiments and cell propagation 
 
HEK293 cells (DSMZ) were cultured in DMEM + 10 % FBS in a water-saturated atmosphere 
at 37 °C and 5 % CO2. Cells were passaged twice a week (1:10). On the day before 
transfection, approx. 2.5·105 cells were seeded in a cavity of a 24-well-plate (Becton 
Dickinson, Heidelberg, Germany). On the day of transfection, cells had reached approx. 90 
% confluence. Cells were transfected with the plasmid pcDNA3.1(+)-Neo-hH2R using 
Lipofectamine™ 2000 (Invitrogen) and cultured in the presence of G418 (Sigma, 400 μg / mL) 
for 4 weeks. These cells were then cotransfected with the plasmid pcDNA3.1(+)-Hygro-qs5-
HA in the same way and cultured in the presence of hygromycin B (Mobitec, Göttingen, 
Germany; 100 μg / mL) and G418 as mentioned before for at least another two months prior 
to the performance of the binding assays.  
Stably transfected HEK293-hH2R-qs5-HA cells were frozen in medium (DMEM + 10 % FBS, 
400 µg / mL G418 and 100 µg / mL hygromycin B) including 10 % DMSO according to the 
procedure described in section 3.2.1.  
 
4.2.3 Determination of ligand affinity in binding assays for the hH2R 
 
4.2.3.1 Radioligand binding assays for the hH2R 
 
4.2.3.1.1 Radioligand binding to whole cells 
 
HEK293-hH2R-qs5-HA cells were cultured in DMEM supplemented with 10 % FBS and 
selection antibiotics (400 μg / mL of G418 and 100 μg / mL of hygromycin B) in a water-
saturated atmosphere containing 5 % CO2 at 37 °C. Cells were passaged (1:10) twice a 
week. For the assays, approx. 5·105 cells were seeded into 175-cm2 culture flasks (Nunc) 
and grown to approx. 70 % confluency (6 days) before the radioligand binding assays. Cells 
were detached with DMEM + 10 % FBS and centrifuged for 5 min at 300 g. Cells were once 
washed in Leibovitz' L-15 medium without phenol red + 1 %,  counted in a hemocytometer 
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and finally suspended in Leibovitz' L-15 medium without phenol red + 1 % FBS according to 
a density of 1-2·106 cells / mL.  
In addition to HEK293-hH2R-qs5-HA cells, HEK293-FLAG-hH2R-His6 cells, which were 
kindly provided by Dr. Dietmar Gross (Institute of Pharmacy, Department of Pharmacology 
and Toxicology, University of Regensburg) were investigated for reference. Those cells were 
cultured in selective medium (DMEM + 10 % FBS + 400 µg / mL G418) and passaged 1:10 
twice a week without Trypsin / EDTA treatment. 
For saturation binding experiments, 20 µL of a ranitidine solution (10 mM in PBS) or 20 µL of 
a PBS-solution were pipetted per cavity of a 96-well plate (Greiner) either for the 
determination of unspecific or total binding, respectively. 160 µL of the cell suspension were 
added per well. Samples were completed by addition of 20 µL of the respective [3H]-tiotidine 
solution (10-fold concentrated feed-solutions compared to final concentration; for further 
information about the tracer see section 3.2.6). Samples were shaken at 100 rpm for 65 min 
under light protection prior to harvesting. Cell-bound radioactivity was transferred to a glass 
fibre filter GF / C (Skatron) pretreated with PEI (0.3 % (v/v); PEI was from Sigma) by the 
Combi Cell Harvester 11025. The filter was washed with PBS (4 °C) for approx. 10 s. Filter 
discs with the cell-bound radioactivity were further handled according to section 3.2.6. 
Decays per minute (dpm) were transferred to Microsoft® Office Excel 2003. In case of 
saturation binding experiments, specific binding was determined by subtraction of unspecific 
binding from the respective values for total binding. Data were transferred to SigmaPlot® 9.0 
and analyzed with the multiple scatter - error bars option. Curve fitting for total and specific 
binding was determined according to the ligand binding, one site saturation option whereas 
unspecific binding was analyzed by the standard curves, linear curve option. As data were 
obtained in 2 independent experiments (in each case n = 3), values for total, unspecific and 
specific binding were plotted in % of the Bmax-value of specific binding against the 
concentration of [3H]-tiotidine (Fig. 4.13). For competition binding experiments, cells were 
incubated with the ligands of interest in presence of either 5 nM (HEK293-hH2R-qs5-HA 
cells) or 10 nM (HEK293-FLAG-hH2R-His6 cells) of [3H]-tiotidine according to the conditions 
for the saturation binding experiments. The dpm values of the samples for unspecific binding 
were subtracted from the investigated concentrations of the respective competitor and the 
samples representing the total binding. Residuals were converted into percentage values. 
The data were analyzed with the multiple scatter - error bars option. Sigmoidal curves were 
calculated with the standard curves, four parameter logistic function. IC50-values were 
converted into Ki-values according to the Cheng-Prusoff equation (Cheng and Prusoff, 
1973): Ki = IC50 · Kd / (Kd + [L]), where [L] represents the concentration of [3H]-tiotidine used 
in competition binding experiments. 
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4.2.3.1.2 Assays on membranes 
 
Membranes of HEK293-hH2R-qs5-HA cells were obtained by analogy with a procedure 
described by MAYER (Mayer, 2002), but cells were not rinsed with homogenizing buffer due 
to the weak adherence of the cells. 
Membranes of Sf9 cells expressing a hH2R-GsαS fusion protein were obtained from the 
Department of Pharmacology and Toxicology (Institute of Pharmacy, University of 
Regensburg).  
For competition binding experiments, membranes were thawed, centrifuged (15,000 g, 15 
min, 4 °C) and resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, 75 mM Tris / 
HCl, pH 7.4). Competition binding experiments were essentially performed as described for 
whole cells. Membrane preparations containing 10 µg (HEK293-hH2R-qs5-HA cells) or 13 µg 
(Sf9 cells expressing hH2R-GsαS fusion proteins) of protein were used per sample. For 
assays performed with membranes, 10 nM of [3H]-tiotidine were used. 
.  
 
4.2.3.2 Squaramide derivatives 
  
Compounds 6-8 were synthesized in our workgroup by Daniela Erdmann. Compounds 6 and 
7 incorporate fluorescent moieties in order to perform fluorescence-based binding assays at 
the flow cytometer or the confocal microscope, respectively. Compound 8 is non-fluorescent 
and represents the cold form of a potential radioligand for the hH2R which can be obtained 
by replacement of the propionyl moiety by a [3H]-propionyl residue
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 Fig. 4.7: Chemical structures of the compounds 6-8. 
  
4.2.3.3 Confocal microscopy 
 
HEK293-hH2R-qs5-HA cells were cultured according to section 4.2.3.1.1.  
2 days prior to microscopy, approx. 4 · 104 HEK293-hH2R-qs5-HA cells were seeded per 
cavity of a Lab-Tek® II 8 Chamber # 1.5 German Coverglass System (Nalge Nunc, 
Naperville, USA) in 200 µL of selective culture medium (DMEM + 10 % FBS + 400 µg / mL 
G418 + 100 µg / mL hygromycin B). 
On the day of the investigation, the selection medium was replaced by 200 µL of Leibovitz' L-
15 medium without phenol red (Invitrogen) containing 1 % FBS. By exchanging the culture 
medium, most cells of the weakly adhering population were removed from the polystyrene 
substrate. Thus, cells were post-incubated at 37 °C for 1.5 h in order to allow reattachment 
prior to microscopy. Subsequently, the sample for the total binding was prepared by addition 
of 200 µL of Leibovitz' L-15 + 1 % FBS including 160 nM of 6 per cavity. Hence, the final 
concentration of 6 was 80 nM. The sample of the unspecific binding was prepared in a 
different cavity in the same way, but famotidine was added according to a final concentration 
of 10 µM. Cells were incubated for 45 min at 37 °C in a water saturated atmosphere without 
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addition of CO2.  Subsequently, the samples were analyzed with a Carl Zeiss Axiovert 200 M 
microscope: the laser scanner LSM 510 was used in combination with the C-Apochromat 40 
x / 1.2 W corr.-objective (Immersol™ W was used for water immersion mediating the 
refraction index of water). Laser excitation was performed with a power of 7 % at 633 nm; 
detection of emitted fluorescence was recorded with the 650 nm long pass filter. The 
scanning mode was plane, multi track, 12 bit. The pinhole was adjusted to 90 µm. 
 
4.2.3.4 Determination of ligand affinity by flow cytometric binding assays 
 
HEK293-hH2R-qs5-HA cells were essentially cultured and prepared for flow cytometric 
measurements as described in section 4.2.3.1.1, but cells were not washed prior to the 
adjustment of their density. For saturation binding or competition binding experiments, 196 
µL of cell suspension were mixed with 2 µL of 6 or 7 (100-fold concentrated feed solutions 
relative to final assay concentration in 30 % DMSO / PBS (v/v)), respectively, and 2 µL of 
100-fold concentrated feed solutions compared to final concentration of the respective 
ligands (famotidine, ranitidine (Sigma), cimetidine, tiotidine (Tocris Cookson) or compound 8, 
respectively) in DMSO. Incubations were peformed for 37 min at room temperature under 
light protection prior to the flow cytometric measurements. In saturation binding experiments, 
unspecific binding was determined in the presence of 30 µM of famotidine. In competition 
binding experiments, samples for total binding (fluorescent tracer) and unspecific binding 
(fluorescent tracer plus 100 µM of famotidine) were included and taken into account for data 
analysis. For the investigation of agonists (histamine, dimaprit and arpromidine), these 
conditions were maintained with the exception that the incubation period was reduced to 15 
min in order to prevent internalization of agonist-occupied receptors. 100-fold concentrated 
feed solutions compared to the final assay concentration of arpromidine and histamine were 
prepared in 30 % DMSO / PBS (v/v)  whereas DMSO was used for the respective solutions 
of dimaprit. For the optimisation of assay parameters, 10-fold concentrated feed solutions 
relative to the final concentration of dimaprit were prepared in PBS. Furthermore, the stock 
solution of 7 (20 µM) was prepared in only 2 % DMSO / PBS (v/v). Consequently, samples 
were prepared by addition of 2 µL of 7 (20 µM) and 20 µL of 10-fold concentrated feed 
solutions of dimaprit to 178 µL of cell suspension leading to a final DMSO concentration of 
0.02 % (v/v) in the assay. Samples were incubated for 15 or 65 min, respectively. Flow 
cytometric measurements were performed with the FACSCaliburTM flow cytometer (Becton 
Dickinson, Heidelberg, Germany) according to the subsequent instrument settings: 
excitation: 488 nm (argon laser, compound 7) or 635 nm (red diode laser, compound 6), 
respectively; threshold forward scatter light (FSC) and sideward scatter light (SSC): 52; 
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secondary parameters: none; FSC: E-1; SSC: 320; Fl-3: 650 (compound 7) or Fl-4: 800 
(compound 6), respectively; gated events: 10000.  
Data were analyzed with WinMDI 2.8: the SSC signals of the investigated cells were plotted 
on the y-axis against their FSC signals on the x-axis. A small subpopulation amounting to 
approx. 3000 cells was identified by gating and taken into account for data analysis. Cells in 
this gate (gated events) were plotted on the y-axis against their fluorescence intensities 
determined in Fl-3 or Fl-4, respectively, resulting in histograms (for an example see section 
4.3.2.3, Fig. 4.18). Geometric means were calculated and transferred to Microsoft® Office 
Excel 2003. In case of saturation binding experiments, specific binding was determined by 
subtraction of unspecific binding from the respective values for total binding.  
Data were transferred to SigmaPlot® 9.0 and analyzed with the multiple scatter - error bars 
option. Curve fitting for total and specific binding was determined according to the ligand 
binding, one site saturation option whereas unspecific binding was analyzed by the standard 
curves, linear curve option. In case of competition binding experiments, the geometric means 
of the samples for unspecific binding were subtracted from the investigated concentrations of 
the respective competitor and the samples representing the total binding. Further data 
analysis was performed by analogy with radioligand binding competition experiments in 
section 4.2.3.1.1.  
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4.3 Results and discussion 
 
4.3.1 Investigation of HEK293 cells for the expression of human histamine 
receptors 
 
4.3.1.1 Expression analysis of human histamine receptors in HEK293 cells at the 
mRNA level 
 
The control mRNA encoding β-actin corresponds to the expected size (304 bp), indicating 
successful mRNA isolation (Fig. 4.8). The mRNA encoding the hH2R was also detected with 
the expected size of 370 bp (Fig. 4.8). By contrast, mRNAs of the hH1R, hH3R or the hH4R 
were not detectable. 
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Fig. 4.8: Determination of histamine 
receptor subtype mRNA in HEK293 cells.  
 
The amplification of plasmids incorporating the hH3R (pVL1392-SF-hH3R) or the hH4R 
(pGEM-3Z-SF-hH4R), respectively, worked accurately under the chosen PCR conditions 
(Fig. 4.9) which underlines the validity of the used method.   
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Fig. 4.9: Confirmation of the suitability of the PCR conditions for the amplification of DNA encoding 
A: the hH3R and B: the hH4R. 
As the detection of mRNA does not mandatorily correlate with the expression of a protein 
(Schneider, 2005), western blot experiments were performed in order to investigate the 
expression of the hH2R in HEK293 cells. 
  
4.3.1.2 Western blot analysis of the hH2R expression 
 
4.3.1.2.1 Development of a method for the characterisation of the hH2R expression    
 
A first experiment, using the mouse anti-FLAG primary antibody and the biotinylated anti-
mouse / rabbit secondary antibody, revealed only a weak band for the positive control in the 
presence of a high background (data not shown). When the primary antibody was omitted, 
an immunopositive reaction was obtained in any investigated sample (Fig. 4.10, A). Thus, the 
biotinylated secondary antibody appeared to be unspecific and was replaced by the 
secondary antibody which is linked to a peroxidase (Fig. 4.10, B). 
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Fig. 4.10: Approaches with the semi-dry western blot technique on membranes. A: Unspecific 
binding of the biotinylated secondary antibody in absence of a primary antibody (red box); B: 
unspecific binding of the anti-FLAG primary antibody and the secondary antibody linked to 
horseradish peroxidase on membranes of HEK293 cells (red box). The indicated numbers represent 
the molecular mass of the respective bands in kDa.   
The use of the secondary antibody linked to peroxidase with the anti-FLAG primary antibody 
revealed signals for the hH2R and the sample with the hH1R and RGS4, respectively (Fig. 
4.10, B). This apparently corresponded to the expected results (Preuss et al., 2007; Seifert et 
al., 2003). However, the HEK293 sample gave a positive reaction, too (Fig. 4.10, B), 
although membranes of HEK293 cells should not contain a FLAG-epitope. Thus, the false-
positive reaction reflects unspecific binding. Therefore, the method of the wet western blot 
was used for further investigations instead of the semi-dry variant. 
The investigation of histamine receptor expression using the anti-FLAG primary antibody and 
the secondary antibody linked to peroxidase led to the expected signals (Fig. 4.11, A). This is 
valid for the sample with the hH1R (Seifert et al., 2003) and that with the hH2R (Preuss et al., 
2007) as well for the membranes of HEK293 and HEK293 T cells, which did not give a 
positive reaction.  
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Fig. 4.11: Approaches with the wet western blot on membranes. A: Specific binding of the anti-
FLAG primary antibody, B: lack of specific binding of the rabbit anti-human histamine H2 receptor 
primary antibody on membranes from Sf9 insect cells expressing the hH2R (red box). The 
indicated numbers represent the molecular mass of the respective bands in kDa.   
When the rabbit anti-human histamine H2 receptor primary antibody was used instead of the 
anti-FLAG primary antibody, the detection of the expected protein failed for membranes from 
Sf9 insect cells which expressed the hH2R including two artificial amino acid attachments 
(FLAG-epitope and hexa-His-tag; Fig. 4.11, B). In order to investigate, if the detection failed 
due to those artificial attachments, membranes from HL-60 HD cells expressing a native 
hH2R which neither incorporates a FLAG epitope nor a hexahistidine tag were prepared 
according to section 4.2.1.2.1 and used as positive control for the determination of the hH2R 
expression (section 4.3.1.2.2).  
 
4.3.1.2.2 Detection of the hH2R protein 
 
The use of membranes from HL-60 HD cells instead of membranes from Sf9 insect cells 
expressing an hH2R with artificial attachments revealed the expected band of 40.1 kDa (Fig. 
4.12; the theoretical molecular mass of the hH2R is 40,098 Da according to 
http://www.uniprot.org/uniprot/P25021, February 2009). Neither in the trace of the negative 
control nor in the traces of membranes from HEK293 or HEK293 T cells, a signal was 
detected (Fig. 4.12). 
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Fig. 4.12: Specific binding of the rabbit 
anti-human histamine H2 receptor primary 
antibody on membranes from HL-60 HD 
cells (red box). The indicated numbers 
represent the molecular mass of the 
respective bands in kDa.   
 
 
Thus, western blot experiments neither revealed a hH2R protein in HEK293 nor in HEK293 T 
cells. Probably, the FLAG epitope or the hexahistidine tag impeded the binding of the rabbit 
anti-human histamine H2 receptor primary antibody on membranes which expressed such an 
artificial variant of the hH2R. Since an alteration of the hH2R pharmacology by those artificial 
attachments can not be ruled out, those residues were excluded in the scope of the cloning 
of the hH2R. Furthermore, the results suggest HEK293 cells to be appropriate for the 
expression of human histamine receptors due to the lack of endogenous histamine receptor 
proteins. As HEK293 T cells are not as widely used in expression studies as HEK293 cells 
(Thomas and Smart, 2005), further experiments were performed with the latter cell line.  
 
4.3.2 Determination of binding data for the hH2R 
 
4.3.2.1 Radioligand binding assays for the hH2R 
 
Saturation binding experiments gave comparable Kd-values for [3H]-tiotidine with both 
investigated cell lines (Fig. 4.13, Table 4.2). Data are in agreement with values reported in 
the literature (Kelley et al., 2001).  
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Fig. 4.13: Saturation binding of [3H]-tiotidine. A: HEK293-FLAG-hH2R-His6 cells. B: HEK293-
hH2R-qs5-HA-cells. Unspecific binding was determined in the presence of 1 mM of ranitidine 
(mean values ± SEM; n = 6).  
The hH2R affinities of ranitidine and standard agonists (arpromidine, dimaprit and histamine) 
determined in competition binding experiments with [3H]-tiotidine were comparable at both 
cell types (Fig. 4.14, A and B; Table 4.2). The Ki-values were calculated according to the 
Cheng-Prusoff equation (Cheng and Prusoff, 1973).  
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Fig. 4.14: Competition binding experiments with various H2R ligands. A: HEK293-FLAG-
hH2R-His6 cells. B: HEK293-hH2R-qs5-HA-cells. Unspecific binding was determined in the 
presence of 1 mM of ranitidine (mean values ± SEM; n = 6, unless otherwise indicated).  
Furthermore, results for the agonists were consistent with regard to data from studies using 
membrane preparations of HEK293-hH2R-qs5-HA cells and whole cells (Fig. 4.15, Table 
4.2). The affinity of arpromidine was lower compared to data reported in literature that were 
determined with membrane preparations of Sf9 cells expressing a hH2R-GsαS fusion protein 
(Fig. 4.15, Table 4.2, (Xie et al., 2006)). This observation might be due to this artificial fusion 
protein because the low affinity binding site of arpromidine was confirmed with the 
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established assay on those membranes expressing the fusion protein whereas a high affinity 
binding site was not detected (Fig. 4.15; Table 4.2; (Xie et al., 2006)). 
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Fig. 4.15: Competition binding experiments 
with various H2R ligands.  
Membranes of Sf9 cells expressing hH2R-GsαS 
(black curve) and of HEK293-hH2R-qs5-HA 
cells (red, blue and green curve). Mean values 
± SEM; n = 3.  
 
 
Table 4.2: Comparison of binding data obtained in radioligand binding assays with reference 
values from literature. Indicated are mean values ± SEM: (Kd) or Ki [µM].
Ligand 
 
     HEK293-hH2R-qs5-HA 
 
        cells            membranes
 
HEK293-FLAG-
hH2R-His6 cells
hH2R-GsαS 
Sf9 
membranes
 
reference data 
from literature 
 
[3H]-tiotidine (0.073 ± 0.013)    (n.d.) (0.036 ± 0.006) (n.d.)   (0.032 ± 0.005)1 
ranitidine  0.172 ± 0.011     n.d. 0.127 ± 0.020 n.d.   0.085 ± 0.0042 
arpromidine      5.4 ± 1.3   3.6 ± 0.7      7.1 ± 2.1 
0.301 
± 
0.100 
0.010 
(0.007-0.017); 
0.450 
(0.230-1.200)3 
dimaprit    67.4 ± 20.2 31.4 ± 8.4    69.7 ± 18.0 n.d.   25 ± 52 
histamine  118.2 ± 53.8 57.3 ± 8.6  116.6 ± 52.1 n.d. 
  81 ± 15;  
  2.0 ± 1.22 
 
 
 
1Kelley et al., 2001; 2Leurs et al., 1994; 3Xie et al., 2006
 
The Ki-values of the H2R ligands ranitidine, dimaprit and histamine were in the same order of 
magnitude as data reported in literature, but there was no hint to a high affinity binding site 
for histamine (Table 4.2; (Leurs et al., 1994)).  
Taken together, the hH2R binding is not significantly affected by the coexpression of the 
receptor and the chimeric G-protein qs5-HA (Table 4.2).  
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4.3.2.2 Specific binding of the fluorescent compound 6 to HEK293-hH2R-qs5-HA cells 
in confocal microscopy 
 
As shown in Fig. 4.16, specific binding of compound 6 was detected in the cell membranes of 
HEK293-hH2R-qs5-HA cells.  
 
   
BA
 
Fig. 4.16: Confocal microscopy of HEK293-hH2R-qs5-HA cells incubated with 80 nM of 6. 
A: total binding and B: unspecific binding (determined in the presence of 10 µM 
famotidine). 
 
 
4.3.2.3 Flow cytometric binding assays for the hH2R 
  
Gating of the data revealed cells which do not correctly express the hH2R (Fig. 4.17): in the 
control sample for the detection of unspecific binding, the fluorescence intensity detected in 
Fl-3 was only in part decreased compared to the total binding (Fig. 4.17, right). Hence, 
compound 7 was not completely displaced by the H2R antagonist famotidine. Therefore, the 
gate was readjusted as shown in Fig. 4.18. 
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Fig. 4.17: Binding of compound 7 to HEK293-hH2R-qs5-HA cells. Cells in the red rectangle (right) 
correctly express the hH2R (Further details are described in the text). 
 
In contrast to the result of the first approach (Fig. 4.17) the small subpopulation of cells 
enclosed by this adjusted gate showed a pronounced difference in total and unspecific 
binding of 7 (Fig. 4.18). Thus, this gate was considered for further data analysis.  
 
 
With Kd-values of 166 ± 39 nM (compound 6) and 181 ± 38 nM (compound 7), the 
investigated fluorescent ligands showed remarkably low extents of unspecific binding at 
HEK293-hH2R-qs5-HA cells (Fig. 4.19).  
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Fig. 4.18: Specific binding of 7 to HEK293-hH2R-qs5-HA cells. Cells in the red triangle of the 
density plot (left) were considered for the calculation of histograms (right).   
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Fig. 4.19: Saturation binding experiments with A: compound 6 and B: compound 7 on HEK293-
hH2R-qs5-HA-cells (mean values ± SEM; n = 3). Unspecific binding was determined in the 
presence of 30 µM of famotidine.   
For the purpose of validation, flow cytometric competition binding experiments using various 
H2R ligands were performed. The fluorescence-labelled compound 7 was used at a 
concentration of 200 nM which is in the range of the Kd-value. All 8 investigated ligands 
decreased the specific binding of the fluorescent probe in a concentration-dependent manner 
(Fig. 4.20). 
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Fig. 4.20: Concentration-dependent 
displacement of 7 (200 nM) by various 
H2R ligands. Unspecific binding was 
determined in the presence of 100 µM of 
famotidine (mean values ± SEM; n = 3). 
 
The Ki-values calculated for standard antagonists (cimetidine, famotidine, ranitidine and 
tiotidine) were in agreement with Kb-values obtained in GTPase activity assays (Table 4.3, 
(Kelley et al., 2001; Preuss et al., 2007)). Except for cimetidine, the affinities determined for 
those antagonists in the flow cytometric assay were significantly lower compared to 
radioligand binding data reported by LEURS (Table 4.3, (Leurs et al., 1994)). Nevertheless, 
the rank order of the Ki-values (famotidine ≈ tiotidine < ranitidine < cimetidine) were 
confirmed in competition binding experiments performed with flow cytometry. Compound 8 
showed an affinity in the same order of magnitude as famotidine and tiotidine. The low 
affinity binding site reported for histamine was determined with 138 ± 15 µM which is in 
agreement with data reported in literature (Leurs et al., 1994). However, a high affinity 
binding site reported by LEURS (2.0 ± 1.2 µM; (Leurs et al., 1994)) was not detected. 
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Table 4.3:  Comparison of the affinities [µM] calculated from the flow cytometric measurements 
with data from literature (mean values ± SEM, unless otherwise indicated).  
Ligand 
Flow cytometry 
Ki [µM] 
GTPase assay 
Kb [µM] 
Radioligand binding assays 
Ki [µM] 
cimetidine 1.847 ± 0.443 1.700 ± 0.4301 0.660 ± 0.2203 
famotidine 0.126 ± 0.006 0.048 ± 0.0101 0.016 ± 0.0033 
ranitidine 0.597 ± 0.164 0.840 ± 0.0941 0.085 ± 0.0043 
tiotidine 0.080 ± 0.009 0.060 (0.030-0.130)2 0.017 ± 0.0063 
dimaprit 311 ± 107 - 25 ± 53 
arpromidine 12 ± 2 - 
0.010 (0.007-0.017); 
0.450 (0.230-1.200)4 
histamine 138 ± 15 - 2.0 ± 1.2; 81 ± 153 
8 0.237 ± 0.041 n.d. n.d. 
 
 
 
1Preuss et. al, 2007; 2Kelley et al., 2001 (numbers in parentheses represent the 95 % confidence 
interval); 3Leurs et al., 1994; 4Xie et al., 2006 (numbers in parentheses represent the 95 % 
confidence interval) 
Further differences with regard to binding data were found for the agonists dimaprit and 
arpromidine (Table 4.3, (Leurs et al., 1994; Xie et al., 2006). As the affinity of dimaprit was 
first determined in presence of 1.30 % (v/v) DMSO, the influence of reduced DMSO 
concentrations on the affinity of dimaprit was investigated (Fig. 4.21). Furthermore, the 
influence of a higher incubation period on the binding data of dimaprit was investigated (Fig. 
4.21). The reduction of the DMSO concentration from 1.30 % (v/v) to 0.02 % (v/v) slightly 
increased the affinity of dimaprit whereas an increase in the incubation period from 15 to 65 
min did not significantly alter the binding data of dimaprit (Fig. 4.21, Table 4.4).  
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Fig. 4.21: Effect of DMSO concentration 
and the incubation period on the affinity of 
dimaprit. Indicated are mean values ± 
SEM; n = 3.  
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Table 4.4: Comparison of Ki-values [µM] determined for dimaprit in the presence of various 
concentrations of DMSO at different incubation periods (mean values ± SEM).   
Incubation period [min] DMSO concentration, % (v/v) Ki-value [µM] 
15 1.30 311 ± 107 
15 0.02 163 ±   50 
65 0.02 116 ±   39 
 
Hence, a possible reason for the reduced affinities determined for famotidine, ranitidine, 
tiotidine and dimaprit compared to data reported by LEURS (Leurs et al., 1994) is the use of 
1.30 % (v/v) DMSO. The results obtained for histamine and arpromidine in the presence of 
only 0.6 % (v/v) DMSO suggest this assumption, too: the calculation of a low affinity binding 
site for histamine revealed a value which is in the same order of magnitude as described in 
literature (Leurs et al., 1994) and the affinity for arpromidine was comparable to data 
obtained in radioligand binding experiments (compare data from table 4.2 and table 4.3)  
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4.4 Summary and conclusions 
 
HEK293-hH2R-qs5-HA cells are appropriate for the performance of both radioligand and flow 
cytometric binding assays for the hH2R. The coexpression of the chimera in HEK293-hH2R-
qs5-HA cells did not significantly influence the hH2R binding properties of the investigated 
ligands.    
In order to avoid the use of the red diode laser which is quite sensitive with regard to 
vibration, flow cytometric competition binding experiments with standard ligands for validation 
were performed with 7, which could be excited with the less susceptible argon laser, 
indispensible in flow cytometry. Those measurements revealed in part lower affinities for 
standard ligands in comparison to radioligand binding data determined within the scope of 
this work or reported in literature, respectively (Table 4.5). Since the use of DMSO was 
identified as a possible reason for these discrepancies, investigations at reduced 
concentrations of DMSO are recommended if possible. In case of famotidine and of tiotidine, 
the omission of DMSO could lead to insufficient solubility. As flow cytometric competition 
binding experiments revealed an affinity of compound 8 comparable to tiotidine, its 
radioactive form incorporating a [3H]-propionyl moiety represents a promising radioligand for 
the hH2R. 
 
Table 4.5: Comparison of binding data determined in flow cytometric and radioligand binding 
experiments on HEK293-hH2R-qs5-HA cells with radioligand binding data reported in literature (Ki 
[µM]; mean values ± SEM). 
 
Ligand 
Flow 
cytometry 
Ki [µM] 
Radioligand binding 
assay  
Ki [µM] 
Reported data  
(Leurs et al., 1994) 
Ki [µM] 
arpromidine    12 ± 2  5.4 ± 1.2   n.d. 
dimaprit 
   311 ± 1071 
   163 ± 502 
   116 ± 393 
            67 ± 20             25 ± 5 
histamine    138 ± 15  118 ± 54   81 ± 15; 2.0 ± 1.2 
ranitidine    0.597 ± 0.164  0.172 ± 0.011   0.085 ± 0.004 
famotidine    0.126 ± 0.006  n.d.   0.016 ± 0.003 
cimetidine    1.847 ± 0.443  n.d.    0.660 ± 0.220 
tiotidine    0.080 ± 0.009  n.d.   0.017 ± 0.006 
 
1 1.30 % (v/v) DMSO, incubation: 15 min 
2 0.02 % (v/v) DMSO, incubation: 15 min 
3 0.02 % (v/v) DMSO, incubation: 65 min 
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5.1 Introduction  
 
Activation of the H2R preferentially leads to recruitment of Gs-proteins which mediate an 
increase in the intracellular cAMP level. Available assay systems for the determination of 
cAMP suffer from several drawbacks. For instance, radiometric proximity assays (Williams, 
2004) use [125I]-cAMP and are consequently accompanied with the general disadvantages of 
radioactivity like high costs due to special handling (Schneider et al., 2006). The 
determination of cAMP in the scope of assays for drug development by FRET-techniques 
(Nikolaev et al., 2004) might be hampered by the relative low signal-to-noise ratio of that kind 
of measurement. Reporter-gene assays for the determination of the intracellular cAMP-level 
offer the advantage of relative high signal-to-noise ratios, but exhibit other drawbacks like the 
need of long incubation periods or the overestimation of low-efficacy agonists (Baker, 2008; 
Hill et al., 2001). In contrast, the determination of receptor-mediated changes in intracellular 
calcium levels is a preferred assay technique in drug discovery ((Siehler, 2008), compare 
also section 3.1). The spectrofluorimetric fura-2 assay was successfully used for the 
determination of ligand activity at several GPCRs in our workgroup, i.e. the neuropeptide Y 
receptors hY1R, hY2R and hY4R  (Gessele, 1998; Ziemek et al., 2006; Ziemek et al., 2007), 
respectively, and the hH1R (Kracht, 2001). However, with regard to the hH2R, the stimulation 
of the receptor by an agonist has to be redirected to an increase in the intracellular calcium 
level. In previous studies, CHO K1 cells were cotransfected with the cDNAs encoding the 
hH2R and the Gα16 protein in order to establish a calcium assay for the hH2R (Schneider, 
2005). Unfortunately, among other difficulties with the transfected cells, an inexplicable 
upregulation of the hH1R was discovered whereas hH2R-mediated calcium transients were 
not detectable (Schneider, 2005). Therefore, in the present work a different approach was 
tried. Choice of cell line, transfection method and selection of cells were performed by 
analogy with a protocol for the cloning of the hH4R (Morse et al., 2001), because an 
upregulation of the hH1R due to the transfection process was not reported in this study 
((Morse et al., 2001); section 4.2.2.4).  
Furthermore, the previously described strategy to redirect the activation of the Gi-coupled 
receptors hY2R and hY4R by coexpression of qi5-HA to an increase in the intracellular 
calcium level (Ziemek et al., 2006; Ziemek et al., 2007) was adapted to the hH2R instead of 
using Gα16. Therefore, in place of qi5-HA, the respective chimeric Gα-protein suited for the 
Gαs-coupled hH2R was used for the establishment of HEK293-hH2R-qs5-HA cells, i.e. qs5-
HA. (see chapter 4). This assay principle was successfully applied to other GPCRs which 
preferentially couple to Gs-proteins like the 5-hydroxytryptamine 5-HT7 receptor (Wood et al., 
2000) or the vasopressin V2 receptor (Conklin et al., 1996).  
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The stable coexpression of mitochondrially targeted apoaequorin (mtAEQ) besides the 
receptor of interest (hY2R, hY4R) and a chimeric Gα-protein enabled the measurement of 
intracellular transients with a bioluminescence assay in the 96-well format (Ziemek et al., 
2006; Ziemek et al., 2007). 
As the bioluminescence signal is a consequence of an enzymatic reaction that is 
accompanied with emission of visible light (λmax = 470 nm), no excitation is needed for the 
creation of the readout signal. Therefore, no autofluorescence is provoked in this assay. In 
addition, luminescent proteins that could impair the measurements are usually absent in 
mammalian cells. Thus, the main advantage of this bioluminescence readout over the 
fluorescence-based assays using calcium-chelating dyes like fura-2 for the determination of 
calcium transients is the considerably elevated signal-to-noise ratio (cf. Ziemek, 2006). Thus, 
this assay was established for the determination of hH2R-ligand activity in addition to the 
fura-2 assay. 
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Fig. 5.1: Bioluminescence reaction and regeneration of aequorin in vitro. Native coelenterazine (R 
= OH) or coelenterazine h (R = H) is converted to the respective coelenteramide accompanied by 
emission of light (adapted from Ziemek, 2006). 
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5.2 Materials and methods 
 
5.2.1 Fura-2 assays for the determination of ligand activity at the hH2R 
 
5.2.1.1 Spectrofluorimetric fura-2 assays 
 
Histamine and famotidine were from Sigma whereas dimaprit was synthesized in our 
laboratories. Histamine and dimaprit were dissolved in PBS, whereas famotidine was 
dissolved in 30 % (v/v) DMSO / PBS as 200-fold concentrated feed solutions with respect to 
the final concentration.  
Furthermore, the acylguanidine 9, a compound which was selected as a representative of a 
new class of bivalent histamine H2R agonists developed in our workgroup (Kraus, 2007), 
was investigated for its agonistic potency and efficacy in the fura-2 assay. The substance 
addresses the hH2R and incorporates two sets of pharmacophoric groups linked by a spacer 
(Fig. 5.2). The investigation of this twin compound in steady-state GTPase assays revealed a 
highly potent (EC50 = 12.4 ± 6.4 nM) partial agonism (53 ± 4 % relative to histamine) on Sf9 
cell membranes expressing a hH2R-GsαS fusion protein (Kraus, 2007). Furthermore, the 
compound proved to be highly selective for the hH2R over other histamine receptors due to 
the introduction of the 2-amino-4-methylthiazol-5-yl moieties instead of imidazol-4-yl residues 
(Kraus, 2007; Kraus et al., 2009). The NG-acylation of the guanidine moieties reduces the 
basicity and accounts for improved pharmacokinetic properties (Ghorai et al., 2008; Kraus et 
al., 2009). 
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Fig. 5.2: Chemical structure 
of the bivalent acylguanidine-
type H2R agonist 9. 
 
 
HEK293-hH2R-qs5-HA-cells were cultured in DMEM supplemented with 10 % FBS and 
selection antibiotics (400 μg / mL of G418 and 100 μg / mL of hygromycin B) in a water-
saturated atmosphere containing 5 % CO2 at 37 °C. Cells were passaged (1:10) twice a 
week. For the calcium assays, approx. 5·105 cells were seeded into 175-cm2 culture-flasks 
and grown to 25-75 % confluency (3-4 days) in the presence of the respective selection 
antibiotics before the assays.  
Cells were loaded with fura-2 / AM according to section 3.2.2. However, due to the relatively 
weak adherence of the cells, the treatment with trypsin / EDTA was omitted. The assay was 
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performed as described for HEL cells by GESSELE (Gessele, 1998). 1 mL of the cell 
suspension (1 · 106 cells / mL) was diluted in a cuvette with 1 mL of loading buffer (for 
composition see section 3.2.2) and continuously stirred in the LS 50 B spectrofluorimeter 
(PerkinElmer, Überlingen, Germany) at 25 °C and low speed. The baseline was recorded for 
approx. 20 s prior to the challenge of the loaded cells by agonists. Antagonists were pipetted 
to the cuvette 15 min prior to the addition of a fixed concentration of agonist. Every fourth 
measurement was a reference signal (investigation of agonists: 1 mM of histamine; 
investigation of antagonists: 10 µM of histamine in the absence of antagonist). Instrument 
settings were: excitation wavelengths: 340 and 380 nm (alternating), slit: 10 nm (in each 
case); emission wavelengths: 510 nm (in each case), slits: 10 nm (in each case); resolution: 
0.1; measurement time: 300 s (maximal). 
For preliminary experiments in section 5.3.1 (Fig. 5.3), raw data were transferred to 
Microsoft® Office Excel 2003 in order to determine ratios. The minimal ratio due to the 
addition of histamine to cotransfected cells challenged in the absence of antagonists (Fig. 
5.3, A; red curve, approx. 24 s) was set as 0 % for the relative calcium increase. The 
maximal relative calcium increase was determined in the absence of antagonist for co-
transfected cells and was set as 100 % (Fig. 5.3, A; red curve, approx. 44 s). All other values 
were related to this 100 % signal. Values were transferred to SigmaPlot® 9.0 for the 
construction of kinetic curves (Fig. 5.3). Calcium concentrations were calculated according to 
the Grynkiewicz equation (Grynkiewicz et al., 1985): 
 
SFB*
)RR(
)RR(
*K=]Ca[
max
min
d
+2
-
-
 
 
The Kd-value represents the dissociation constant of the fura-2-Ca2+ complex. R is the ratio 
of emission at 510 nm after excitation at 340 and 380 nm, respectively. Rmax is the 
fluorescence ratio in presence of saturating Ca2+ concentration, determined after cell lysis 
and subsequent saturation of fura-2 with the calcium ions of the surrounding loading buffer 
by addition of digitonin (10 µL of an aqueous solution; 2 % (v/v); digitonin was from Sigma, 
Deisenhofen, Germany). Rmin represents the ratio in the absence of free Ca2+, determined 
after addition of EGTA (50 µL of a 600 mM solution in Tris, 1 M, pH 8.7) to cells that were 
lysed with digitonin. SFB is a correction factor representing the emission at 510 nm after 
excitation at 380 nm of the Ca2+ free and the Ca2+ saturated dye, respectively. 
Calculated calcium concentrations were transferred to SigmaPlot® 9.0 for the depiction of 
kinetic measurements (Fig. 5.4). For the construction of concentration response curves, 
calculated calcium concentrations were converted into percentage values and analyzed with 
SigmaPlot® 9.0 according to the multiple scatter, error bars option. Curve fitting was 
performed with the standard curves, four parameter logistic function.  
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5.2.1.2 The fura-2 assay in the 384-well format 
 
Arpromidine and cimetidine were synthesized in our laboratories whereas tiotidine was from 
Tocris Cookson (Ballwin, USA). HEK293-hH2R-qs5-HA cells were cultured and prepared for 
the fura-2 assays according to section 5.2.1.1.  
In general, samples were in part randomized in order to exclude misinterpretations due to 
different time periods between the loading procedure with fura-2 / AM and the registration of 
the fluorescence (i.e. time period of post-incubation).   
Agonists were characterised by analogy with the procedure described in section 3.2.4.1, 
investigations in 384 well-plates. However, a blank value (pure PBS without agonist) was 
included for every investigated concentration of dimaprit and arpromidine.  
Feed solutions of 9 were prepared 5-fold concentrated with respect to the final concentration 
in DMSO / PBS 1.5 % (v/v). Accordingly, the determination of blank values, arpromidine 
controls and histamine references (1 mM) in assays with 9 were performed in presence of 
0.3 % (v/v) of DMSO, too. 
Investigations of reference antagonists and H2R ligands 6-8 (consider section 4.2.3.2) were 
performed as explained in 3.2.4.2.2 with minor modifications: 100-fold concentrated feed 
solutions compared to final assay concentration were prepared in DMSO. 1 µL of the 
respective solution was pipetted in the cavities of the 384-well plate. 89 µL of the fura-2 
loaded cells (1 · 106 cells / mL) were added per well. Incubations were performed for 15 min 
under light protection at room temperature without shaking. Calcium transients were elicited 
with 10 µL of histamine in PBS (100 µM). Thus, the final concentration of DMSO in 
antagonist assays was 1 % (v/v). Investigations of antagonists were performed with 120 
measurement cycles except for tiotidine (46 cycles).  
Data analysis was performed by subtraction of the blank value from the samples of the 
respective concentration and from the histamine reference. Further data analysis was 
performed according to section 3.2.7.  
 
5.2.2 The aequorin assay for the functional characterisation of hH2R ligands 
in the 96-well format 
 
5.2.2.1 Transfection of HEK293-hH2R-qs5-HA cells and selection 
 
The pMTAEQ vector incorporating the gene encoding mitochondrially targeted apoaequorin 
(mtAEQ) was a generous gift from Prof. Dr. Stan Thayer, Department of Pharmacology, 
University of Minnesota, USA. The cDNA of mtAEQ was subcloned in the pcDNA3.1(+)-Zeo 
vector (Invitrogen, Karlsruhe, Germany) by ZIEMEK (Ziemek et al., 2006). 
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HEK293-hH2R-qs5-HA cells were cultured and passaged as explained in 5.2.1.1. Cells were 
seeded in a 24-well plate according to 4.2.2.4. 4 d after seeding, cells had reached approx. 
95 % confluence. Cells were transfected with the plasmid pcDNA3.1(+)-Zeo-mtAEQ using 
Lipofectamine™ 2000 (Invitrogen) and cultured according to 5.2.1.1 including Zeocin™ (100 
μg / mL; InvivoGen, San Diego, USA) for 4 weeks prior to the performance of 
bioluminescence assays.  
Stably transfected HEK293-hH2R-qs5-HA-mtAEQ cells were frozen in medium (DMEM + 10 
% FBS, 400 µg / mL G418, 100 µg / mL hygromycin B and 100 µg / mL Zeocin™) including 
10 % DMSO as described in section 3.2.1.  
 
5.2.2.2 Preparation of the cells, assay performance and data analysis 
 
Approx. 5 · 105 HEK293-hH2R-qs5-HA-mtAEQ cells were seeded into 175-cm2 culture-flasks 
and incubated in a water saturated atmosphere at 37 °C and 5 % CO2 in the presence of all 
selection antibiotics (G418, hygromycin B and Zeocin™). Due to the slow growth, cells were 
just propagated to approx. 25 % confluency (10-14 d) before the assays. 
Cells were prepared for the assay as described previously (Ziemek et al., 2006) with minor 
modifications: cells were detached by DMEM + 10 % FBS without trypsin / EDTA treatment 
and centrifuged at 300 g for 5 min. Cells were resuspended in DMEM without phenol red 
(Invitrogen) including 1 % of FBS, counted and adjusted to a density of 1 · 107 cells / mL. 
Coelenterazine h (500 µM stock solution in methanol; Biotrend, Köln, Germany) was added 
to a final concentration of 2 µM to the cells. Cells were incubated under light protection at 
room temperature without movement for 2 h. The cells were diluted with loading buffer (for 
composition see section 3.2.2) to a density of 5 · 105 cells / mL and incubated for another 3 h 
under light protection at room temperature and gentle stirring. 
The cavities of a white 96-well plate (Greiner, Frickenhausen, Germany) were provided with 
18 µL of the 10-fold concentrated feed solutions compared to the final concentration of the 
ligands (arpromidine: PBS; 9: DMSO / PBS 3 % (v/v)). In general, samples were in part 
randomized in order to exclude misinterpretations due to different time periods between the 
incubation with Coelenterazine h and the registration of the luminescence (i.e. time period of 
post-incubation).   
162 µL of the gently stirred cell suspension (5 · 105 cells / mL) were injected after cycle 4 
(approx. 0.9 s) with a speed of 25, 100 or 200 µL / s, respectively. For the consumption of 
residual coelenterazine h, 20 µL of a triton-X-100 solution (Roth, Karlsruhe, Germany; 1 % 
(v/v) in loading buffer) were injected before cycle 200 (200 µL / s) per sample. Luminescence 
was recorded for another 100 cycles. Thus, the whole measurement lasted 300 cycles 
according to approx. 66 s. 
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Instrument settings were: measurement mode: luminescence; integration time (manual): 200 
ms; attenuation: none; time between move and integration: 50 ms; well kinetic number: 300; 
well kinetic interval (minimal): 220 ms; injector A delay: 880 ms; injector B delay: 45400 ms; 
injection mode: standard. 
For every investigated concentration, a blank value (PBS in case of the validation with 
arpromidine or DMSO / PBS 3 % (v/v) for the characterisation of 9, respectively) was 
determined. A maximal calcium response was determined with histamine (1 mM) in the same 
way. 
Luminescence [RLU] was plotted against time [s] and the area under the peak was 
calculated with SigmaPlot® 9.0. For the total luminescence, cycle 1-300 was taken into 
account, whereas the agonist-mediated response was calculated from cycle 1-199. 
Fractional luminescence was determined as ratio of the agonist-mediated area under the 
peak and that of the total luminescence. The blank value was subtracted from the 
investigated samples of the respective concentration and from the histamine signal. Residual 
values were related on the histamine reference. Sigmoidal curves were established with the 
multiple scatter – error bars option. Curve fitting was realized with the standard curves - four 
parameter logistics function.  
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5.3 Results and discussion 
 
5.3.1 Determination of ligand activity at the hH2R with the fura-2 assay 
 
HEK293-hH2R-qs5-HA cells responded with a strong increase in the intracellular calcium 
level upon stimulation with histamine (30 µM), whereas the untransfected cells showed no 
significant calcium transient upon agonist challenge (Fig. 5.3, A). The signal was completely 
suppressed by the hH2R antagonist famotidine but remained unaffected by the hH1R 
antagonist mepyramine (Fig. 5.3, B).  
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Fig. 5.3: Investigation of HEK293-hH2R-qs5-HA cells in the spectrofluorimetric fura-2 assay.  
A: Histamine-induced calcium response in cotransfected cells compared to wild-type cells 
B: Effect of mepyramine and famotidine on the histamine-induced calcium signal in HEK293-
hH2R-qs5-HA-cells. 
HEK293-hH2R-qs5-HA-cells responded in a concentration-dependent manner to histamine 
(Fig. 5.4).  
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Fig. 5.4: Concentration-dependent increase 
in the intracellular calcium-level by histamine 
in HEK293-hH2R-qs5-HA cells. 
Data analysis enabled the construction of sigmoidal concentration-response curves. Dimaprit 
behaved as a partial agonist using histamine (1 mM) as reference (Fig. 5.5, A). The hH2R 
antagonist famotidine decreased the histamine-induced calcium signal in a concentration-
dependent manner (Fig. 5.5, B). 
100 Chapter 5.3  
c (agonist) [µM]
0.01 0.1 1 10 100 1000
in
tra
ce
llu
la
r c
al
ci
um
 [%
]
0
20
40
60
80
100 histamine (n=4-6)
dimaprit (n=3)
c (famotidine) [µM]
0.0001 0.001 0.01 0.1 1 10 100
0
20
40
60
80
100 n = 3-5
in
tra
ce
llu
la
r c
al
ci
um
 [%
]
 
A B
 
Fig. 5.5: Influence of agonists and the antagonist famotidine on the calcium transients in HEK293-
hH2R-qs5-HA cells (mean values ± SEM; n as indicated). A: Concentration-dependent increase in 
the intracellular Ca2+ level induced by histamine and dimaprit. The maximal calcium signal was 
elicited with 1 mM of histamine. B: Concentration-dependent decrease in the histamine (10 µM)-
stimulated Ca2+ response by famotidine.  
In order to economize the characterisation of putative hH2R ligands with the fura-2 assay, 
measurements were performed in the 384-well format. Injection of the fura-2 loaded cells to 
various concentrations of histamine led to a concentration-dependent increase in the 
intracellular calcium level (Fig. 5.6, A). Increasing amounts of famotidine almost completely 
suppressed the histamine-induced calcium transient in HEK293-hH2R-qs5-HA cells (Fig. 5.6, 
B). The injection of PBS, which was used as the solvent for histamine, in the presence of 50 
µM famotidine led to a comparable increase in the calcium signal as monitored after the 
addition of histamine (10 µM), indicating the injection process to account for that alteration of 
the calcium level (Fig. 5.6, B). This effect corresponding to 21.6 % of the maximal histamine 
signal (n=5) was taken into account by subtraction from raw data (compare also section 
3.3.2.2.1) when H2R antagonists were investigated. 
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HEK-293-hH2R-qs5-HA-cells responded in a concentration-dependent manner to histamine. 
Data analysis enabled the calculation of sigmoidal curves. Dimaprit and arpromidine were 
characterised as partial agonists compared to histamine (1 mM) as reference (Fig. 5.7, A). 
The H2R antagonists cimetidine, famotidine and tiotidine decreased the histamine-induced 
calcium signal in a concentration-dependent manner (Fig. 5.7, B). The Kb-values of the 
antagonists were calculated according to CHENG and PRUSOFF (Cheng and Prusoff, 
1973).  
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Fig. 5.6: Investigation of fura-2 loaded HEK293-hH2R-qs5-HA cells in 384-well microtitre plates. 
A: Effect of increasing amounts of histamine on the intracellular Ca2+ level B: Effect of increasing 
amounts of famotidine on the histamine-induced calcium signal and influence of the PBS-injection. 
Calcium signals were registered as the ratio of emission at 535 nm after excitation at 340 nm and 
380 nm, respectively.  
A B
A B
 
Fig. 5.7: Sigmoidal curves for agonists and antagonists. A: Concentration-dependent increase in 
the intracellular Ca2+ level by histamine, dimaprit and arpromidine. B: Concentration-dependent 
decrease in the histamine (10 µM)-stimulated Ca2+ response by cimetidine, famotidine and 
tiotidine. Mean values ± SEM, n as indicated. 
The results obtained in spectrofluorimetric measurements were in agreement with those 
obtained in 384-well plates. As exemplarily confirmed for tiotidine, the reduction of the 
measurement time from 120 cycles to 46 cycles did not impair the determination of the 
antagonistic activity (Fig. 5.7, B). 
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A summary of data determined in fura-2 assays compared to data reported in literature is 
shown in Table 5.3: results obtained in fura-2 assays mainly agree with data determined in 
GTPase activity assays (Kelley et al., 2001; Preuss et al., 2007). However, a higher potency 
was found in the GTPase assay for dimaprit (Preuss et al., 2007). Similar observations were 
previously made for histamine on the hH1R: in the GTPase assay on membranes of hH1R 
expressing Sf9 cells, an EC50-value of 184 ± 94 nM was determined (Seifert et al., 2003), 
whereas in the fura-2 assay on U-373 MG cells, the EC50-value was in the low micromolar 
range (see chapter 3 and (Kracht, 2001)). Discrepancies may result from differences of both 
assay systems. On the one hand, human cells co-express an unmodified hH2R and the 
chimera qs5-HA, whereas hH2R-GsαS fusion proteins in membranes from Sf9 insect cells are 
used in the scope of GTPase assays. In addition, the hH2R used in GTPase assays 
incorporates a FLAG epitope and a hexahistidine tag. Finally, in the GTPase assay, an event 
close to receptor activation is measured whereas the calcium response is an effect more 
downstream in the signalling cascade, and the readout systems are remarkably different 
(liquid scintillation counting versus fluorescence emission). 
Furthermore, the results from the fura-2 assay correspond to data which were determined in 
a fluo-3 assay (Esbenshade et al., 2003). However, dimaprit showed a decreased potency 
and efficacy relative to histamine on clone B1 of the investigations performed by 
ESBENSHADE (Esbenshade et al., 2003) compared to the results of the fura-2 assay (this 
thesis) and data obtained for clone A5 by ESBENSHADE (Esbenshade et al., 2003). A 
possible reason for this observation is a difference in constitutive activity of those cell types. 
In general, a decrease in constitutive activity is accompanied with a decrease of potency 
observed for agonists. Furthermore, the effect mediated by partial agonists compared to full 
agonists is decreased in such systems, too (Preuss et al., 2007). Thus, clone B1 
(Esbenshade et al., 2003) might be less constitutively active than clone A5 (Esbenshade et 
al., 2003) and HEK293-hH2R-qs5-HA cells. 
Recently, H2R ligands were investigated in cAMP assays (Baker, 2008). The order of 
potency and efficacy obtained in fura-2 assays for histamine and dimaprit was in agreement 
with data from those cAMP measurements. The antagonistic activities determined in the 
paper of BAKER (Baker, 2008) were in the same order of magnitude as data obtained in 
fura-2 assays. However, the potencies of both agonists were higher in cAMP measurements 
than in fluo-3 assays (Esbenshade et al., 2003) and fura-2 assays, presumably, due to 
preferential coupling of the hH2R to Gαs rather than Gαq (Esbenshade et al., 2003).  
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Table 5.1: Comparison of pharmacological data determined in fura-2 assays (spectro-
fluorimeter and 384-well plate) with results published in literature. Mean values ± SEM, 
unless otherwise indicated. 
 
 
 
H2R ligands synthesized in our workgroup were investigated in the fura-2 assay. For assays 
with compound 9 in 384-well plates, arpromidine was used as a reference compound at two 
concentrations (0.2 and 20 µM). Whereas arpromidine showed agonistic activity as expected, 
under the same conditions 9 did not show a concentration-dependent response. In contrast, 
the intracellular calcium-level was only slightly altered up to a concentration of 1000 nM 
whereas 3000 nM of 9 evoked a steep increase in [Ca2+]i. Similar observations were made 
for 10000 and 30000 nM of 9 (Fig. 5.8). In contrast, in spectrofluorimetric measurements, 
compound 9 behaved as highly potent partial agonist on HEK293-hH2R-qs5-HA cells (the 
 
1Esbenshade et al., 2003: 2clone A5, 3clone B1; EC50 values were determined from pEC50 values 
± SEM; 4Preuss et al., 2007; 5Kelley et al., 2001 (Numbers in parentheses represent the 95 % 
confidence interval) 
 
Fura-2 assay 
(384-well format) 
 
Fura-2 assay 
(spectro-
fluorimeter) 
 
 
Fluo-3 assay1 
 
 
 
GTPase assay 
 
 
 
 
 
Ligand  
 
intrinsic 
activity 
 
EC50  
or Kb 
[µM] 
 
 
intrinsic
activity 
 
EC50 
or Kb 
[µM] 
 
 
intrinsic
activity 
 
EC50 
or Kb 
[µM] 
 
 
intrinsic 
activity 
 
EC50  
or Kb 
[µM] 
histamine 1.00 
 
 1.40 
± 0.55 
 
1.00 
 
    0.83 
 ± 0.29 
 
   1.002 
 
   1.003 
   0.71-0.782 
 
   1.66-1.823 
 
 1.004 
 
    0.99 
 ± 0.094 
dimaprit    0.88 ± 0.03 
 
 14.00 
± 4.14 
 
    0.83 
 ± 0.09 
 
    6.74 
 ± 4.38 
 
 ≈ 0.802 
 
 ≈ 0.503 
 11.48-13.182 
 
 41.69-63.103 
    0.85 
 ± 0.024 
 
    0.91 
 ± 0.434 
 
arpromidine    0.72 ± 0.03 
   0.18 
± 0.05 n.d. n.d. n.d. n.d. 
    0.84 
 ± 0.034 
    0.07 
 ± 0.014 
cimetidine -    1.89 ± 0.56 - n.d. n.d. n.d. - 
    1.70 
 ± 0.434 
famotidine -    0.05 ± 0.01 - 
    0.08 
 ± 0.04 n.d. n.d. - 
    0.05 
 ± 0.014 
tiotidine -    0.07 ± 0.01 - n.d. n.d. n.d. - 
    0.06 
   (0.03- 
  0.13)5 
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final assay concentration of DMSO was 0.25 % (v/v) in spectrofluorimetric measurements 
(Fig. 5.8, Table 5.2).  
c (compound) [nM]
1 10 100 1000 10000
in
tra
ce
llu
la
r c
al
ci
um
 [%
]
0
10
20
30
40
50
60 9 (spectrofluorimeter, n=2)
9 (384-well format, n=5-10)
arpromidine 
(384-well formate, control; n=5)
 
Fig. 5.8: Influence of various 
concentrations of 9 on the intracellular 
calcium level in HEK293-hH2R-qs5-HA 
cells determined with the 384-well format 
and the spectrofluorimeter. Mean values 
± SEM; n as indicated. 
 
Compared to the results from the GTPase assay on membrane preparations from Sf9 cells 
expressing a hH2R-GsαS fusion protein (Kraus, 2007), slightly lower potency and intrinsic 
activity was found for 9 in the spectrofluorimetric calcium assay on HEK293-hH2R-qs5-HA 
cells (Table 5.2). Thus, HEK293-hH2R-qs5-HA cells proved to be in principle suited for the 
characterisation of 9, but the application of the fura-2 assay in the 384-well format failed in 
this case. A possible explanation for this unexpected result might be the relative low dynamic 
range in fura-2 assays performed in the 384-well format (Fig. 5.6, A). In addition, even in the 
spectrofluorimetric fura-2 assay with its higher dynamic range (Fig. 5.4), a partial agonism of 
only approx. 40 % intrinsic activity relative to histamine was detected for 9 (Fig. 5.8). Thus, 
the relatively low efficacy of 9 and the instrument settings of the fura-2 assay in the 384-well 
format might hamper the appropriate characterisation of 9. 
Therefore, the aequorin assay with its increased signal-to-noise ratio compared to the fura-2 
assay (Ziemek, 2006) was established (section 5.3.2) in order to overcome that problem. 
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Table 5.2: Comparison of pharmacological data determined for compounds 6-9 
in the fura-2 assay and the GTPase assay. Indicated are mean values ± SEM. 
 
 
 
Fura-2 assay 
(384-well format) 
 
 
Fura-2 assay  
(spectrofluorimeter) 
 
 
GTPase assay 
 
 
 
 
Ligand 
 
intrinsic 
activity 
EC50 
or Kb 
[µM] 
 
intrinsic 
activity 
EC50 
or Kb 
[µM] 
 
intrinsic 
activity 
EC50 
or Kb 
[µM] 
 
6 
 
- 
 
120 ± 30 
 
- 
 
n.d. 
        
- 
 
98 ± 262 
 
7 
 
- 
 
130 ± 34 
 
- 
 
n.d. 
        
- 
 
22 ± 22 
 
8 
 
- 
 
150 ± 20 
 
- 
 
n.d. 
        
- 
 
43 ± 82 
 
9 
 
failed 
 
failed 
 
0.42 ± 0.01 
 
 
60 ± 10 
 
0.53 ± 0.041 
 
12 ± 61 
1Kraus, 2007; 2Erdmann, D., 2009, personal communication 
Compounds 6-8 suppressed the histamine-induced calcium signal in a concentration-
dependent manner with comparable antagonistic activities (Table 5.2, Fig. 5.9). 
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Fig. 5.9: Influence of various concentrations of 
compounds 6-8 on the intracellular calcium 
level evoked with histamine (10 µM) in 
HEK293-hH2R-qs5-HA cells (384-well format). 
Mean values ± SEM; n = 6. 
 
In the GTPase assays, compounds 6 and 8 showed antagonistic activities comparable to 
results in fura-2 assays whereas 7 showed a higher antagonistic activitiy (Table 5.2).  
In order to investigate the reliability of calcium signals with respect to the time period 
between the loading procedure with fura-2 / AM and the registration of the fluorescence (i.e. 
time period of post-incubation), the potency and efficacy of arpromidine as well as of the 
antagonistic activity of famotidine were determined in the 384-well format. 
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With respect to arpromidine, only the samples measured immediately after termination of the 
loading procedure provided reliable results (1-64 min, 72 samples). Concentration-response 
curves constructed from data collected after prolongued post-incubation exhibited an 
increase in the signal obtained at the lowest concentration of arpromidine. Accordingly, the 
concentration-response curves seemed to be shifted to the left and the respective EC50 
values dropped compared to data obtained directly after termination of the loading procedure 
(Fig. 5.10, Table 5.3).  
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Table 5.3: Comparison of pharmacological data calculated from sigmoidal curves shown in Fig. 5.10. 
Indicated are mean values ± SEM (n =5). Further details are described in the text. 
 
 
Time period of post-incubation  
[min] 
 
 
EC50 [µM] 
 
Intrinsic activity,  
relative to histamine = 100 [%] 
     
1-  64 
 
0.259 ± 0.159 
 
87 ±   5 
 
115-170 
 
0.100 ± 0.103 
 
85 ±   4 
 
180-234 
 
0.039 ± 0.188 
 
93 ± 11 
 
306-340 
 
0.239 ± 0.108 
 
90 ±   3 
Fig. 5.10: Concentration-dependent increase 
of the intracellular calcium level by arpromidine 
determined at various time periods of post-
incubation in HEK293-hH2R-qs5-HA cells 
(fura-2 assay, 384-well format). Further details 
are described in the text. Mean values ± SEM; 
n = 5.  
 
In view of famotidine, measurements performed within the time period from 165 to 357 min 
after termination of loading with fura-2 / AM still led to a concentration-dependent decrease 
of the histamine-induced calcium-signals by the antagonist (Fig. 5.11).  
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Fig. 5.11: Concentration-dependent decrease 
in the intracellular calcium level elicited with 
histamine (10 µM) by famotidine in HEK293-
hH2R-qs5-HA cells at various time periods of 
post-incubation (fura-2 assay, 384-well format). 
Further details are desbribed in the text. Mean 
values ± SEM; n as indicated in Table 5.4.  
 
 
 
 
Time period of post-
incubation  
[min] 
 
 
n 
 
 
IC50 [µM] 
 
 
Kb [µM] 
 
15-  57 
 
9 
 
0.442 ± 0.043 
 
0.054 ± 0.005 
 
165-207 
 
3 
 
0.159 ± 0.080 
 
0.020 ± 0.010 
 
315-357 
 
3 
 
0.115 ± 0.064 
 
0.014 ± 0.008 
 
Table 5.4: Comparison of pharmacological data determined for famotidine at various times periods 
of post-incubation (mean values ± SEM, n as indicated). Further details are described in the text. 
The calculated IC50-values and the respective Kb-values were in the same order of 
magnitude at every investigated time frame (Table 5.4). Thus, experiments should be 
feasible up to a measurement time of approx. 6 h. 
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5.3.2 The aequorin assay in the 96-well format for the determination of hH2R 
ligand activity 
 
Arpromidine and the reference compound, histamine, led to concentration-dependent 
increases in the luminescence signal upon injection of the cells (Fig. 5.12, A). In contrast, the 
injection of triton-X-100 provoked lower luminescence signals for agonist-pre-stimulated 
samples than for the sample of the blank value due to the consumption of a diminished 
amount of residual coelenterazine h (Fig. 5.12, B). 
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Fig. 5.12: Aequorin assay for 
arpromidine with histamine as 
reference in HEK293-hH2R-qs5-HA-
mtAEQ cells. A: injection of cell-
suspension (100 µL / s) B: injection 
of triton-X-100 (200 µL / s). B A 
 
Arpromidine was recognized as a partial agonist relative to histamine irrespective of the 
chosen injection speed (Fig. 5.13, A). The assay performed with an injection speed of 25 µL / 
s revealed - despite a good signal-to-noise ratio - a lower potency and efficacy relative to 
histamine, respectively, compared to data obtained with fura-2 assays in the 384-well format 
(Table 5.1 and 5.5; Fig. 5.13 A, B). By contrast, the potency obtained at an injection speed of 
200 µL / s was in agreement with the result of the fura-2 assay, but the intrinsic activity 
relative to histamine was still slightly decreased. In addition, the signal-to-noise ratio was 
considerably decreased compared to the results obtained at lower speed of injection (Table 
5.1 and 5.5; Fig. 5.13 A, B). 
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An injection speed of 100 µL / s led to the most reliable data: the potency of arpromidine was 
comparable to data from the fura-2 assay. The efficacy relative to histamine was slightly 
decreased at this injection speed, too (Table 5.1 and 5.5; Fig. 5.13 A). The signal-to-noise 
ratio was comparable to that obtained at an injection speed of 25 µL / s but in each case 
higher than for 200 µL / s (Fig. 5.13, B).  
Table 5.5: Comparison of pharmacological data obtained for arpromidine at various injection  
speeds in the aequorin assay. 
 
Injection speed [µL / s] 
 
 
EC50 [µM] 
 
intrinsic acitivity, relative to 
histamine = 100 [%] 
25 1.47 ± 0.50 39 ± 9 
100 0.33 ± 0.05 63 ± 2 
200 0.15 ± 0.09 61 ± 7 
 
Fig. 5.13: Influence of the speed of injection of suspended HEK293-hH2R-qs5-HA-mtAEQ on A: the 
calculation of sigmoidal curves (mean values ± SEM; n = 4); B: the signal-to-noise ratio in the aequorin 
assay (mean values ± SEM; n = 6). 
Thus, the injection speed of 100 µL / s enabled the correct estimation of the pharmacological 
properties of arpromidine accompanied with an appropriate signal-to-noise ratio (Table 5.1, 
Table 5.5; Fig. 5.13, B).  
For assays with compound 9, arpromidine was used as reference at two concentrations (200 
and 20000 nM, "arpromidine (control)" in Fig. 5.14). Those reference compounds showed 
agonistic activity as expected, however, under the same conditions, 9 did not exhibit a 
concentration-dependent response up to a concentration of 300 nM.  
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Fig. 5.14: Influence of various 
concentrations of 9 on the intracellular 
calcium level in HEK293-hH2R-qs5-HA-
mtAEQ cells determined with the 
aequorin assay (speed of injection of the 
cell-suspension: 100 µL / s). The red 
curve shown in Fig. 5.13 is here depicted 
again for comparison (arpromidine 
(validation). Mean values ± SEM; n = 4. 
 
Higher concentrations of 9 were not investigated because the results for concentrations up to 
300 nM were comparable to those determined in the 384-well format with the fura-2 assay. 
As the data for arpromidine determined in the aequorin assay and in 384-well plates using 
the fura-2 assays were comparable regarding potency and efficacy relative to histamine, it is 
unlikely that concentrations of 9 higher than 300 nM would lead to a concentration-
dependent increase in the intracellular calcium level (see section 5.3.1). Hence, the 
determination of the pharmacological properties of the bivalent H2R agonist 9 was not 
achieved by using the aequorin assay (Fig. 5.14). 
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5.4 Summary and conclusions 
 
The stable coexpression of the hH2R and the chimeric Gα-protein qs5-HA in HEK293 cells 
enabled the establishment of the fura-2 assay for the hH2R. Standard H2R agonists 
(histamine, arpromidine and dimaprit) and H2R antagonists (famotidine, cimetidine and 
tiotidine) were characterised in the spectrofluorimetric and in the 384-well microtitre assay 
format. The results for histamine and dimaprit were consistent with data reported for a fluo-3 
assay (Esbenshade et al., 2003) and were predominantly in agreement with results obtained 
in GTPase activity assays. However, dimaprit showed a decreased potency in fura-2 assays 
compared to results from GTPase assays (Preuss et al., 2007). Agonistic potencies were 
lower in fura-2 assays than in cAMP assays reported in literature (Baker, 2008) whereas 
antagonistic activities of cimetidine, famotidine and tiotidine were in agreement with data 
reported in literature (Kelley et al., 2001; Preuss et al., 2007), as well by reduction of the 
measurement time from 120 to 46 cycles. Investigations on the reliability of calcium signals 
with respect to the time period between the loading procedure with fura-2 / AM and the 
registration of the fluorescence (i.e. time period of post-incubation) revealed an appropriate 
characterisation of 72 samples (measurement time: 64 min) in the agonist-mode after loading 
of the cells. In case of antagonists, reliable measurements should be feasible up to approx. 6 
h after termination of loading. The investigation of the compounds 6-8 with the fura-2 assay 
in the 384-well format revealed antagonistic activities in the same order of magnitude (Kb = 
120 – 150 nM). Since the characterisation of the potent partial hH2R agonist 9 succeeded at 
the spectrofluorimeter with the fura-2 assay but failed in the 384-well format, HEK293-hH2R-
qs5-HA cells were stably cotransfected with mtAEQ in order to establish a calcium assay 
with an improved signal-to-noise ratio. The characterisation of arpromidine led to data that 
were in agreement with those determined in fura-2 assays or reported in literature, 
respectively (Preuss et al., 2007). The characterisation of 9 in the microtitre format failed with 
this alternative readout, too. Therefore, the characterisation of bivalent H2R agonists like 
compound 9 at whole cells in functional assays is to date most convenient with the 
spectrofluorimetric fura-2 assay. 
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G-protein coupled receptors (GPCRs) are one of the largest superfamilies in the druggable 
human genome, targeted by a significant portion of the currently available pharmaco-
therapeutics and are considered promising biological targets for drug discovery programmes. 
With respect to the pecularities of this class of drug targets, the research projects of the 
Graduiertenkolleg (Research Training Group) Medicinal Chemistry (GRK 760) address 
histamine receptors as prototypes of aminergic GPCRs, their ligands (agonists, antagonists, 
modulators) and signal transduction (second messenger, signal proteins, gene regulation) at 
the molecular level. As a part of this Graduate Training Programme, this thesis aimed at the 
development of binding and functional in vitro assays for the human histamine H1, H2 and H4 
receptor, respectively. Such methods are required for both the screening of compound 
libraries and the detailed pharmacological characterisation of compounds in terms of affinity, 
quality of action (agonism or antagonism) and receptor subtype selectivity.  
 
Whereas the ratiometric fura-2 based calcium assay in cuvettes has been state of the art for 
the determination of intracellular calcium for decades, this method has not become a 
standard procedure in the microtitre plate format. Instead, non-ratiometric dyes such as fluo-
4 are preferred in high throughput screening. In order to combine the advantages of 
ratiometric calcium measurements with increased throughput in the microplate format, 
human H1R (hH1R) expressing U-373 MG cells were used as a model. Compared to the 
conventional protocol, the sequence of the test procedure had to be changed, e.g. for 
agonists fura-2 loaded cells were injected into the wells containing the test compounds. The 
characterisation of the agonist histamine yielded reliable data both in 96-well and 384-well 
plates. The determination of antagonistic activity was most effective in the 384-well format. 
The procedure was validated and optimized using standard H1R antagonists. Sequential 
reduction of the measurement time enabled the characterisation of 480 samples in one 
assay per day in the 384-well format. As a proof-of-concept, the applicability of this approach 
was confirmed by the identification of potent hH1R antagonists as lead compounds from a 
library of more than thousand new chemical entities provided by a pharmaceutical company.  
 
Due to the lack of appropriate wild-type cells expressing the hH2R or the hH4R, transfection 
experiments using the well characterised HEK293 cells were performed to establish cellular 
binding and functional assays. Since little information has been available on the expression 
pattern of human histamine receptor subtypes, those cells were investigated both on the 
mRNA level and by Western blot. Although a band corresponding to the hH2R was identified 
by mRNA analysis, the respective receptor protein was not detected in Western blots. 
Therefore, HEK293 cells were considered appropriate for the expression of human histamine 
receptor subtypes. 
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To establish a functional assay, HEK293 cells were stably co-transfected with the hH2R and 
the chimeric Gα-protein qs5-HA, thereby redirecting the agonist-mediated receptor 
stimulation to a robust calcium signal. For validation, radioligand binding experiments were 
performed comparing the co-transfected cells (HEK293-hH2R-qs5-HA cells) with HEK293-
FLAG-hH2R-His6 cells as reference. The affinities determined for the investigated standard 
ligands were on both cell types and on membranes from HEK293-hH2R-qs5-HA cells in the 
same order of magnitude and mainly in agreement with data reported in literature, except for 
the H2R agonist arpromidine, which showed lower affinity than reported for binding 
experiments performed in a different model (hH2R-GsαS fusion proteins). Generally, the 
binding properties of the investigated ligands were not significantly influenced by the co-
expression of qs5-HA in HEK293-hH2R-qs5-HA cells.  
As an alternative to the use of hazardous and expensive radioligands, fluorescence-based 
binding assays were developed. The specific binding of a cyanine-dye-labelled H2R ant-
agonist to HEK293-hH2R-qs5-HA cells was visualized by confocal microscopy. In addition, 
flow cytometric saturation binding experiments were performed on HEK293-hH2R-qs5-HA 
cells with this cyanine-labelled compound and with a pyrylium-dye (Py)-labelled H2R ligand. 
The fluorescent ligands showed moderate submicromolar affinities, but remarkably low 
extents of unspecific binding. Affinities determined in binding experiments by displacing the 
Py-labelled ligand with H2R standard ligands were slightly lower for some compounds than 
reference data from literature, possibly due to the presence of DMSO in the assay 
(supported by investigations using varying DMSO concentrations).  
For the determination of the functional activity of hH2R ligands, fura-2 assays were 
established in cuvettes and in the microtitre format. Data obtained in the fura-2 assays were 
in agreement with results reported for calcium measurements performed with fluo-3 and were 
essentially in the same order of magnitude as reported for GTPase activity.  
Preliminary experiments aiming at the development of binding and functional assays for the 
hH4R were performed as described in the appendix.  
Taken together, the established flow cytometric binding assay using fluorescence-labelled 
ligands and stably co-transfected cells represents an innovative alternative to radioligand 
binding assays for the determination of ligand affinity on the hH2R. The principle of stable co-
expression of receptor and chimeric Gqs5-protein allowed the development of fluorescence-
based calcium measurements, which can be performed in the microtitre format, thereby 
enabling reasonable throughput. The developed methods will contribute to the 
characterisation of compounds on histamine receptor subtypes with regard to affinity, 
receptor subtype selectivity, quality of action and potency. 
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1 Introduction 
 
Fig. 2: Map of the pGL4.29[luc2/CRE/Hygro] vector 
(Promega, Mannheim, Germany). The luc2P gene 
which encodes the luciferase is under control of CRE. 
The hygromycin resistance (Hyg) enables the stable 
expression in mammalian cells whereas the ampicillin 
resistance (Amp) accounts for the amplification of the 
vector in competent bacteria.   
 
998)), is added.  
 
In order to develop assays for the determination of ligand affinity and activity at the human 
histamine H4 receptor, HEK293 cells should be stably co-transfected with the cDNA 
encoding the receptor and proteins enabling an appropriate readout to perform functional 
assays. In principle, the latter can be achieved by coupling the receptor to the chimeric Gα-
protein qi5-HA (Conklin et al., 1996; Conklin et al., 1993; Morse et al., 2001) in order to 
redirect the hH4R signalling to an intracellular calcium response. A cAMP-response element 
(CRE)-driven reporter gene assay represents an attractive alternative, since the H4R is 
coupling to Gi-proteins resulting in a decrease in intracellular cAMP levels (de Esch et al., 
2005). In this case, stimulation of the adenylyl cyclase activity is required to enable the 
quantification of the cAMP-decreasing effect induced by H4R stimulation. Therefore, the 
diterpene forskolin (Fig. 1), a direct activator of the adenylyl cyclase (AC; (Tang and Hurley,
1
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Fig. 1: Chemical structure of the diterpene forskolin. 
 
Elevated cAMP levels switch on protein kinase A (PKA), which phosphorylates various 
proteins including CRE-binding protein, which in turn binds to the CRE. In genetically 
engineered cells, the CRE signalling cascade can be coupled to reporter gene expression, 
r instance luciferase (Fig. 2).  
 
fo
 
 
The enzyme luciferase is capable of converting the substrate D-luciferin into oxyluciferin 
accompanied by an emission of visible light detectable in luminometers (Fig. 3; (Bronstein et 
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l., 1994)). Hence, the luminescence signals increase with the expression of the luciferase in 
a cAMP-dependent manner and decrease with hH4R receptor activation, respectively.  
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R (Kd = 1.1 nM) and the hH4R (Kd = 5.1 nM). The non-labelled 
old") ligand UR-PI294 behaved as an almost full agonist at the hH4R in GTPase assays 
(Emax = 0.90; (Igel et al., 2009). 
  
4R were characterised in radioligand binding 
experiments using the radioligand [3H]UR-PI294 (Igel et al., 2009), which displays high 
affinity for both the hH3
Fig. 3:  Conversion of D-luciferin by firefly luciferase to oxyluciferin (according to (Shinde et al., 
2006)). 
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In order to avoid misleading interpretation
 
Fig. 4: Chemical structure of [3H]UR-PI294, the 
radioligand used for the binding experiments with 
hH4R-transfected cells. 
s due to agonist-mediated receptor internalization, 
e influence of various incubation periods on the binding behaviour of the radioligand to 
H4R-tansfected cells was investigated.  
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h
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2 Materials and methods 
 
2.1 Propagation of DNA, cell culture and transfection experiments 
 
The vector pcDNA3.1(+)-Neo-hH4R was from the Guthrie cDNA resource center (Sayre, 
USA). Transformation of competent E. coli TOP10 bacteria, isolation and characterisation of 
DNA were performed according to section 4.2.2.1. Sequencing revealed no mutation in the 
cDNA encoding the hH4R. HEK293 cells (Deutsche Sammlung für Mikroorganismen und 
Zellkulturen (DSMZ), Braunschweig, Germany) were cultured and transfected with the vector 
incorporating the cDNA encoding the hH4R as described in section 4.2.2.4. Cells were then 
cultured in presence of G418 (400 µg / mL) for 4 weeks. Cells were either cotransfected with 
pcDNA3.1(+)-Hygro-qi5-HA (Ziemek et al., 2006) or pGL4.29[luc2/CRE/Hygro] (Promega, 
Mannheim, Germany), respectively, in the same way and cultured in each case for at least 
another 4 weeks in the presence of hygromycin B (100 µg / mL in each case) prior to the 
performance of assays. The established cell types were named HEK293-hH4R, HEK293-
hH4R-qi5-HA or HEK293-hH4R-CRE-Luc, respectively. Cells were frozen in medium (DMEM 
+ 10 % FBS + respective selective antibiotics) including 10 % DMSO as described in section 
3.2.1. In addition, HEK293-FLAG-hH4R-His6 cells were established and provided by David 
Schnell (Institute of Pharmacy, Department of Pharmacology and Toxicology, University of 
Regensburg). He used HEK293 cells from the American Type Culture Collection (ATCC, 
Rockville, USA) and performed transfection experiments with FuGENE® HD (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. Ratios of 
transfection reagent [µL] to DNA [µg] of 4 to 2 and 6 to 2 were chosen. Transfected cells 
were cultured in DMEM + 10 % of FBS including 800 µg / mL of G418 for selection and 
further handled in presence of 600 µg / mL of G418 (Schnell, D., 2009, personal 
communication).     
 
2.2 Spectrofluorimetric fura-2 assay 
 
HEK293-hH4R-qi5-HA cells were cultured as mentioned for HEK293-hH2R-qs5-HA cells in 
section 5.2.1.1 and prepared for fura-2 assays according to section 3.2.2 without trypsin / 
EDTA treatment. 200-fold concentrated feed solutions with respect to final assay 
concentrations of histamine were prepared in PBS. Fura-2 loaded cells were investigated in 
spectrofluorimetric measurements as described in section 5.2.1.1 (investigation of agonists).  
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2.3 Reporter gene assay 
 
Approx. 3.3 · 104 HEK293-hH4R-CRE-Luc cells were seeded per cavity of a 24-well plate 
(Becton Dickinson, Heidelberg, Germany) in DMEM without phenol red (Invitrogen, 
Karlsruhe, Germany) supplemented with 10 % FBS and selective antibiotics (400 µg / mL of 
G418 and 100 µg / mL of hygromycin B). Cells were grown to 50 % confluency within 4 days 
at 5 % CO2 and 37 °C in a water saturated atmosphere. For the assays, cell culture medium 
was carefully replaced with fresh medium (composition as mentioned above) including 
histamine at concentrations ranging from 0.1 to 10.000 nM. The cells were incubated with the 
agonist for 10 min. Samples were either not challenged or induced by addition of forskolin 
according to final assay concentrations of 100 or 1000 nM, respectively. Cells were cultured 
for 5 h as mentioned before. The medium was removed and 60 µL of lysis buffer (Biotium, 
Hayward, USA) were added per well. The cells were incubated under occasional tapping for 
20 min at room temperature. Samples were transferred to microfuge tubes and centrifuged 
for 10 min at 11,000 rpm in a table top centrifuge. 30 µL of the supernatant from each 
reaction vessel were transferred into luminometer tubes. For the luminescence readouts, the 
injector of the luminometer Lumat LB 9501 (Berthold, Bundoora, Australia) was primed with 
the solution of D-luciferin in luciferase assay buffer (0.2 mg / mL; Biotium). Light emission 
was induced by injection of 100 µL of the D-luciferin solution per sample. Luminescence 
signals were recorded as relative light units [RLU]. In order to diminish errors due to different 
cell numbers per well, the comparability of the conditions was controlled, i.e. the protein 
amount was determined for every investigated well: 5 µL of each supernatant were pipetted 
into a cuvette and diluted with 95 µL of Millipore water. 1 mL of the 1:5 diluted Protein Assay 
Dye Reagent Concentrate (Bio-Rad Laboratories) was added per cuvette. Samples were 
mixed and investigated at 595 nm after 10 min by VIS spectroscopy. Protein amounts were 
calculated by a calibration curve determined with HSA (Behringwerke, Marburg, Germany). 
 
2.4 Radioligand binding experiments 
 
The established cell types described in section 2.1 were cultured and prepared for the 
radioligand binding experiments according to section 4.2.3.1.1. Transparent 96-well plates 
(Greiner) were either provided with 20 µL of PBS for the determination of total binding or 20 
µL of thioperamide (100 µM) as samples for unspecific binding, respectively. 160 µL of the 
cell suspension were added per well. Samples were completed by addition of 20 µL of the 
radioactive tracer [3H]UR-PI294 (50 nM in PBS). Samples were incubated at 100 rpm and 
room temperature for 5, 15, 30, 60 or 90 min, respectively. Further processing of the samples 
was performed as described in section 4.2.3.1.1.  
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3 Results and discussion 
 
3.1 Spectrofluorimetric fura-2 assay 
 
Loaded cells were challenged with various concentrations of histamine: neither 0.1, nor 3, 
nor 30 µM of histamine evoked a calcium response in HEK293-hH4R-qi5-HA cells (data not 
shown).  
 
3.2 Reporter gene assay 
 
The samples that were not challenged by forskolin showed comparable signals at every 
investigated concentration of histamine. The induction of the cells by either 100 or 1000 nM 
of forskolin led to a clear increase in the luminescent response, respectively. Unfortunately, 
histamine neither suppressed the cAMP-responses in samples challenged with 100 nM of 
forskolin nor in those induced by 1000 nM of forskolin (Fig. 5). 
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Fig. 5: Influence of various 
concentrations of histamine on 
the readout. Samples were either 
not challenged or induced with 
100 or 1000 nM of forskolin 
(FSK), respectively (mean values 
± SEM; n = 3). 
*Samples for the luminescence 
readout were diluted 1:100 prior 
to the measurements. 
 
As neither calcium-transients (section 3.1) nor alterations of the intracellular cAMP-level were 
observed, the established cell types were investigated in radioligand binding assays in order 
to investigate ligand binding to the H4R.  
 
3.3 Radioligand binding experiments 
 
Neither HEK293-hH4R cells, nor HEK293-hH4R-qi5-HA cells, nor HEK293-hH4R-CRE-Luc 
cells showed a specific binding of the tracer (Fig. 6). 
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Fig. 6: Investigation of hH4R-transfected cells in radioligand binding experiments. A: HEK293-
hH4R; B: HEK293-hH4R-qi5-HA; C: HEK293-hH4R-CRE-Luc cells (mean values ± SEM; n = 3). 
In contrast, 10 µM of thioperamide displaced the radioactive tracer on HEK293-FLAG-hH4R-
His6 cells transfected with a ratio of 4 µL transfection reagent to 2 µg DNA after incubation 
periods of 60 or 90 min, respectively. With regard to HEK293-FLAG-hH4R-His6 cells 
transfected according to a ratio of 6 µL transfection reagent to 2 µg DNA, no significant 
differences in the presence or absence of thioperamide were observed, respectively (Fig. 7). 
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Fig. 7: Investigation of HEK293-FLAG-hH4R-His6 cells in radioligand binding experiments. Cells 
transfected with a ratio of A: 4 µL transfection reagent to 2 µg DNA; B: 6 µL transfection reagent to 2 
µg DNA. Indicated are mean values ± SEM; n = 3. 
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4 Summary and outlook 
 
Transfection of HEK293 cells (DSMZ) with the cDNA encoding the native hH4R using 
Lipofectamine™ 2000 (Invitrogen) as the transfection reagent and subsequent selection did 
not result in a cell type appropriately incorporating the receptor of interest as revealed by 
radioligand binding experiments. In contrast, HEK293-FLAG-hH4R-His6 cells that were 
established by David Schnell (Institute of Pharmacy, Department of Pharmacology and 
Toxicology, University of Regensburg) by transfection of HEK293 cells (ATCC) with the 
cDNA encoding a modified hH4R (FLAG-hH4R-His6) by FuGENE® HD (Roche Diagnostics) 
with a ratio of 4 µL transfection reagent to 2 µg DNA led to a specific binding of [3H]UR-PI294 
(approx. 50 % specific binding, compare Fig. 7, A). Given an incubation period of 90 min, 
recent radioligand binding experiments performed in our workgroup with HEK293-FLAG-
hH4R-His6 cells according to both transfection approaches led to even more promising 
results: specific binding of [3H]UR-PI294 was at least determined with 70 % (Nordemann, U., 
2009, personal communication). Thus, those cell types seem to be suited for the 
development of radioligand binding assays, and with appropriate fluorescent ligands flow 
cytometric measurements could become feasible. With respect to a cellular functional assay 
for the hH4R, the stable coexpression of a CRE-driven reporter gene (see above) seems 
promising, as similar successful approaches with transiently expressed reporter genes are 
described in literature (Lim et al., 2005; Liu et al., 2001). Given its commercial availability, a 
plasmid incorporating a serum-response-element (SRE)-driven luciferase and an appropriate 
eukaryotic marker would represent an alternative approach to establish a reporter gene 
assay. As the stimulation of the hH4R leads to activation of the MAP-kinase pathway (de 
Esch et al., 2005; Morse et al., 2001), which accounts for an increased SRE-driven 
transcription (Hill and Treisman, 1995; Hill et al., 2001), readouts could become feasible that 
are directly and not inversely proportional to receptor activation as it would be the case in a 
forskolin-dependent CRE-driven reporter gene assay for the hH4R.  
As the stimulation of the hH4R was successfully coupled to an increase in intracellular 
calcium levels by stable coexpression of Gα16 (Crane and Shih, 2004), the corresponding 
genetic modification of HEK293-FLAG-hH4R-His6 cells should enable a fura-2 assay for the 
hH4R (compare chapters 3 and 5). In addition, the disadvantage to overestimate low-efficacy 
agonists in reporter gene assays (Hill et al., 2001) could be overcome by this assay format. 
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